sir
william
osler
note
fourth
edit
book
principl
practic
medicin
widespread
fatal
acut
diseas
pneumonia
captain
men
death
centuri
later
promin
pneumonia
clinic
entiti
remain
remain
among
top
common
caus
death
among
age
group
unit
state
singl
common
caus
infectionrel
mortal
clinic
challeng
communityacquir
pneumonia
cap
involv
wide
array
everincreas
number
microbi
agent
caus
diseas
tabl
difficulti
make
clinic
etiolog
diagnosi
fact
singl
antimicrobi
regimen
cover
possibl
caus
specif
etiolog
diagnosi
often
possibl
time
initi
treatment
begun
clinician
must
decid
empir
therapi
appropri
increas
preval
antibiot
resist
among
mani
common
pathogen
made
challeng
difficult
understand
pathogenesi
diseas
evalu
relev
data
care
histori
physic
examin
recognit
common
clinic
pattern
infect
inform
microbiolog
laboratori
aid
narrow
possibl
etiolog
agent
pneumonia
therebi
allow
reason
therapi
select
empir
lung
constantli
expos
mixtur
gase
particul
materi
microb
constitut
inspir
air
although
lower
respiratori
tract
tradit
consid
steril
recent
investig
use
cultureindepend
techniqu
shown
normal
healthi
individu
similar
microbiota
upper
lower
respiratori
tract
although
lower
concentr
microorgan
within
lung
complex
microbiota
demonstr
individu
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
signific
variat
microbiota
differ
locat
within
lung
individu
develop
acut
pulmonari
infect
appear
aris
defect
host
defens
exposur
particularli
virul
microorgan
overwhelm
inoculum
infecti
agent
gain
entri
lower
respiratori
tract
aspir
upper
airway
resid
microbiota
inhal
aerosol
materi
less
frequent
metastat
seed
lung
blood
pulmonari
defens
system
involv
innat
adapt
immun
includ
anatom
mechan
barrier
humor
immun
cellmedi
immun
phagocyt
activ
tabl
upper
airway
includ
nasopharynx
oropharynx
larynx
site
first
expos
inhal
microorgan
nasal
mucosa
contain
ciliat
epithelium
mucusproduc
cell
mechan
clearanc
entrap
organ
occur
nasopharynx
via
expuls
swallow
oropharynx
flow
saliva
slough
epitheli
cell
local
product
complement
bacteri
interfer
resid
microbiota
serv
import
factor
local
host
defens
secretori
immunoglobulin
iga
major
immunoglobulin
produc
upper
airway
account
total
protein
nasal
secret
possess
antibacteri
antivir
activ
despit
rel
poor
opsonin
despit
controversi
low
iga
level
probabl
associ
increas
bacteri
infect
igg
igm
enter
airway
predominantli
via
transud
blood
role
bacteri
opson
complement
activ
agglutin
neutral
activ
similar
note
serum
pneumonia
common
caus
infectionrel
death
predomin
pathogen
communityacquir
pneumonia
cap
adult
includ
streptococcu
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
speci
staphylococcu
aureu
enter
gramneg
bacilli
less
frequent
caus
produc
sever
diseas
predomin
pathogen
patient
recent
hospit
nurs
home
resid
includ
aureu
aerob
gramneg
rod
includ
pseudomona
aeruginosa
mix
aerobicanaerob
organ
typic
clinic
manifest
coughth
sine
qua
non
pneumoniasputum
product
dyspnea
chest
pain
fever
fatigu
sweat
headach
nausea
myalgia
occasion
abdomin
pain
diarrhea
gram
stain
cultur
sputum
sampl
remain
valuabl
diagnost
assay
blood
cultur
obtain
patient
immunocompromis
health
careassoci
hcap
hospitalacquir
pneumonia
hap
hospit
sever
cap
chest
radiograph
obtain
patient
suspect
pneumonia
sever
biomark
includ
procalcitonin
creactiv
protein
assess
discriminatori
assay
defin
popul
higher
likelihood
bacteri
infect
could
benefit
antibiot
therapi
clinic
util
assay
yet
establish
one
three
sever
index
score
psi
use
assess
need
hospit
immunocompet
patient
cap
similar
indic
use
defin
need
intens
care
unit
admiss
antibiot
therapi
pneumonia
start
soon
diagnosi
consid
like
advanc
macrolid
respiratori
fluoroquinolon
agent
princip
antibiot
use
treatment
cap
coverag
aureu
mix
anaerob
consid
select
situat
see
tabl
suggest
agent
dosag
antibiot
treatment
hcap
includ
coverag
potenti
drugresist
aureu
aerob
gramneg
bacilli
set
includ
coverag
pseudomona
aeruginosa
see
tabl
suggest
agent
dosag
durat
intraven
treatment
inpati
hospit
total
intraven
oral
antibiot
therapi
cap
guid
patient
clinic
stabil
provid
immun
appropri
influenza
pneumococc
vaccin
encourag
cessat
tobacco
smoke
epitheli
cell
line
conduct
airway
submucos
gland
alveoli
produc
airway
surfac
liquid
complex
mixtur
protein
peptid
mix
plasma
transud
airway
surfac
liquid
contain
lysozym
lactoferrin
secretori
leukocyt
proteinas
inhibitor
possess
microbicid
activ
respiratori
epitheli
cell
produc
potent
antimicrobi
peptid
includ
cathelicidin
peptid
possess
individu
antimicrobi
activ
well
synergist
antimicrobi
activ
addit
may
act
chemokin
memori
cell
dendrit
cell
therebi
serv
link
innat
adapt
immun
system
bacteria
size
particl
may
reach
termin
airway
alveoli
mucociliari
apparatu
exist
level
yet
varieti
humor
cellmedi
host
defens
function
alveolarlin
fluid
contain
surfact
fibronectin
igg
complement
effect
opsonin
surfact
compos
sever
compon
spa
spb
spc
spd
serv
increas
microbicid
capac
macrophag
compound
may
also
affect
freerad
product
lymphocyt
activ
spa
spd
collectin
famili
collagen
carbohydratebind
protein
protein
bind
varieti
organ
includ
virus
gramneg
gramposit
bacteria
mycobacteria
fungi
may
decreas
virul
enhanc
phagocytosi
neutrophil
alveolar
macrophag
free
fatti
acid
lysozym
ironbind
protein
defensin
also
present
may
directli
microbicid
phagocyt
cell
includ
macrophag
neutrophil
play
major
role
pulmonari
host
defens
four
distinct
popul
macrophag
exist
lung
vari
locat
function
alveolar
macrophag
locat
alveolarlin
fluid
interphas
air
lung
tissu
serv
resid
phagocyt
cell
lower
airway
first
phagocyt
encount
inert
particl
potenti
pathogen
enter
lung
via
inspir
air
alveolar
macrophag
play
sever
critic
role
phagocyt
cell
elimin
certain
organ
number
adher
microorgan
epitheli
surfac
upper
airway
critic
initi
step
colon
subsequ
infect
chang
fibronectin
secret
bind
characterist
epithelium
variou
lectin
occur
respons
underli
diseas
may
help
explain
colon
occur
clinic
set
other
particl
greater
effici
filter
hair
anterior
nare
impact
onto
mucos
surfac
configur
upper
airway
nasal
turbin
cough
epiglott
reflex
also
keep
larg
particul
matter
reach
central
airway
trachea
conduct
airway
transbronchi
tree
usual
effect
entrap
particl
sharp
angl
central
airway
branch
caus
particl
impact
mucos
surfac
entrap
endobronchi
mucu
entrap
particl
remov
ciliat
epithelium
oropharynx
organ
increas
beyond
macrophag
capabl
handl
organ
involv
particularli
virul
eg
pseudomona
aeruginosa
macrophag
becom
mediat
inflammatori
respons
produc
cytokin
recruit
neutrophil
lung
interstiti
macrophag
locat
lung
connect
tissu
serv
phagocyt
cell
antigenprocess
cell
dendrit
cell
deriv
monocyt
locat
within
epithelium
trachea
conduct
airway
termin
airway
alveolar
septa
pulmonari
vasculatur
viscer
pleura
cell
therefor
posit
interact
antigen
inhal
air
dendrit
cell
special
subpopul
term
langerhan
cell
possess
enhanc
capac
captur
process
present
class
ii
antigen
migrat
lymphoid
tissu
stimul
tcell
immun
respons
dendrit
cell
also
produc
varieti
cytokin
chemokin
includ
interleukin
il
serv
stimul
bcell
immun
function
intravascular
macrophag
locat
capillari
endotheli
cell
cell
activ
phagocyt
remov
foreign
damag
materi
enter
lung
via
bloodstream
neutrophil
recruit
crucial
inflammatori
respons
lung
mechan
involv
initi
detect
organ
lung
gener
subsequ
resolut
respons
clearli
delin
lung
parenchym
cell
may
also
help
regul
inflammatori
respons
addit
epitheli
cell
interstiti
macrophag
dendrit
cell
endotheli
cell
pulmonari
smooth
muscl
cell
fibroblast
produc
proinflammatori
eg
colonystimul
factor
chemokin
antiinflammatori
factor
microorgan
express
molecular
recognit
pattern
uniqu
differ
host
pattern
recognit
receptor
famili
tolllik
receptor
present
epithelioid
cell
alveolar
macrophag
dendrit
cell
well
cell
locat
strateg
area
lung
either
individu
recognit
lead
gener
earlyrespons
cytokin
tumor
necrosi
ili
activ
transcript
factor
mitogenactiv
protein
kinas
phosphoinositid
nuclear
factor
kappa
b
interferonregulatori
factor
transcript
factor
serv
common
pathway
pattern
recognit
receptor
orchestr
develop
inflammatori
respons
mediat
transcript
chemokin
adhesin
molecul
cytokin
signal
cascad
serv
two
purpos
first
gener
maintain
inflammatori
respons
recruit
neutrophil
area
microbi
invas
goal
activ
antiinflammatori
respons
mediat
lead
shed
receptor
neutral
cytokin
inhibit
macrophag
recruit
serv
ensur
inflammatori
respons
held
check
noninvolv
area
lung
injur
balanc
proinflammatori
antiinflammatori
cytokin
effector
molecul
allow
steril
infect
area
lung
without
gross
destruct
lung
addit
recogn
polymorph
defect
uncommonli
found
pattern
recognit
receptor
inflammatori
antiinflammatori
mediat
genet
variat
contribut
individu
suscept
pneumonia
cellmedi
immun
via
lymphocyt
macrophag
central
adapt
immun
respons
lung
especi
import
certain
pathogen
includ
virus
intracellular
organ
surviv
within
pulmonari
macrophag
eg
mycobacterium
legionella
lymphocyt
within
lung
found
along
epitheli
surfac
le
well
within
interstiti
intravascular
space
le
cell
predominantli
memori
cell
interact
epitheli
cell
dendrit
cell
interstiti
cell
similarli
predominantli
cell
differ
ratio
seen
either
le
cell
intravascular
lymphocyt
destroy
respiratori
epithelium
may
disrupt
normal
ciliari
activ
neutrophil
function
includ
chemotaxi
phagocytosi
stimul
oxid
metabol
alveolar
macrophag
function
may
also
inhibit
certain
viral
infect
sepsi
associ
extrapulmonari
infect
may
undermin
lung
defens
mechan
anim
model
exposur
lipopolysaccharid
endotoxin
decreas
lung
clearanc
bacteri
challeng
infect
human
immunodefici
viru
hiv
compromis
mani
compon
pulmonari
host
defens
quantit
defect
involv
cell
initi
memori
cell
deplet
rapidli
later
infect
function
defect
caus
viru
includ
impair
respons
remot
recal
antigen
inhibit
respons
solubl
antigen
follow
time
decreas
tcell
respons
alloantigen
mitogen
impair
product
decreas
immunoglobulin
product
balt
destruct
dendrit
cell
degener
lymphoid
follicl
note
defect
antigen
present
dendrit
cell
also
observ
abnorm
chemotaxi
phagocytosi
oxid
metabol
neutrophil
patient
acquir
immunodefici
syndrom
aid
describ
iatrogen
manipul
bypass
interfer
usual
host
defens
upper
airway
endotrach
tube
nasogastr
tube
respiratori
therapi
machineri
predispos
infect
varieti
commonli
prescrib
drug
includ
aspirin
erythromycin
aminophyllin
shown
alter
host
defens
vitro
model
clinic
signific
uncertain
recent
data
macrolid
suggest
immunomodulatori
activ
could
benefici
effect
set
class
agent
includ
proton
pump
inhibitor
histamin
type
receptor
antagonist
antipsychot
agent
associ
pneumonia
populationbas
studi
although
associ
challeng
exact
pathophysiolog
mechan
determin
factor
impair
pulmonari
host
defens
includ
hypoxemia
acidosi
toxic
inhal
pulmonari
edema
uremia
malnutrit
immunosuppress
agent
mechan
obstruct
recent
clinic
studi
also
shown
increas
risk
pneumonia
therapeut
hypothermia
use
manag
cardiac
arrest
head
trauma
older
adult
increas
risk
develop
pneumonia
see
chapter
although
numer
factor
play
import
role
regard
includ
increas
number
increas
sever
underli
diseas
increas
number
hospit
agerel
impair
host
defens
less
effect
mucociliari
clearanc
abnorm
elast
recoil
may
lead
less
effect
cough
clear
upper
airway
popul
elderli
patient
increas
incid
microaspir
chang
humor
immun
cellmedi
immun
function
document
older
person
although
role
develop
infect
remain
unclear
immun
dysregul
shown
occur
elderli
lowgrad
inflamm
occur
lung
absenc
clinic
detect
infect
recurr
episod
bacteri
pneumonia
suggest
presenc
specif
predispos
factor
children
young
adult
recurr
pneumonia
associ
defect
host
defens
includ
recurr
aspir
asthma
congenit
cardiac
pulmonari
diseas
alter
immun
function
congenit
defect
ciliari
activ
cystic
fibrosi
clinic
entiti
associ
recurr
pneumonia
young
person
structur
lung
abnorm
bronchiectasi
pulmonari
sequestr
also
import
predispos
factor
younger
older
patient
popul
becom
known
molecular
basi
inflammatori
respons
becom
clear
varieti
genet
polymorph
exist
associ
predisposit
develop
pneumonia
import
recogn
defect
may
associ
narrow
rang
potenti
pathogen
may
aid
identif
defect
although
congenit
defect
host
defens
appear
childhood
common
variabl
hypogammaglobulinemia
may
first
appear
adulthood
recurr
pneumonia
acquir
host
defens
defect
abund
natur
killer
cell
addit
although
uncommon
adult
childhood
organ
lymphoid
tissu
collect
lung
locat
follicl
along
bronchial
tree
term
bronchusassoci
lymphoid
tissu
balt
collect
balt
collect
appear
morpholog
similar
peyer
patch
intestin
similarli
associ
vasculatur
mucos
epithelium
inhal
antigen
therefor
abl
cross
epitheli
surfac
immedi
encount
cell
involv
antigen
process
antigen
process
present
b
lymphocyt
local
stimul
becom
memori
cell
effector
cell
antibodi
product
occur
tissu
antigen
inhal
alveolu
captur
antigenpres
cell
subsequ
activ
intraalveolar
lymphoid
cell
cell
stimul
migrat
memori
lymphocyt
area
lead
local
accumul
antigenspecif
b
lymphocyt
mani
possess
effector
cell
function
true
anatom
area
bind
cell
endothelium
critic
first
step
inflammatori
process
mediat
interact
leukocyt
functionassoci
antigen
lfa
integrin
lymphocyt
cell
surfac
ligand
expos
endothelium
area
inflamm
intercellular
adhes
molecul
vascular
cell
adhes
molecul
express
ligand
pulmonari
endothelium
upregul
inflammatori
mediat
well
bacteri
lipopolysaccharid
lymphocyt
lung
sever
major
role
lung
includ
product
antibodi
cytotox
activ
includ
kill
viral
infect
cell
product
inflammatori
mediat
mediat
immun
toler
lung
contain
varieti
cytotox
cell
includ
natur
killer
cell
antigen
nonrestrict
antibodydepend
cytotox
cell
antigenrestrict
cytotox
cell
pulmonari
cell
produc
larg
number
cytokin
mous
model
suggest
unstimul
cell
produc
mainli
stimul
convers
memori
cell
two
distinct
group
cytokin
produc
helper
tcell
pattern
cytokin
product
note
murin
model
occur
human
although
appear
less
restrict
cell
produc
contribut
cellmedi
immun
wherea
cell
produc
contribut
humor
immun
function
furthermor
granulocytemacrophag
colonystimul
factor
chemokin
secret
phenotyp
cell
involv
cellmedi
inflammatori
reaction
wherea
cell
stimul
antibodi
product
especi
ige
stimul
eosinophil
activ
howev
appear
respons
mani
immun
respons
interact
tregulatori
cell
mucos
dendrit
cell
appear
mediat
phenomenon
immun
toler
lung
defens
lung
function
normal
extrem
effici
maintain
low
microbi
concentr
lower
airway
howev
number
factor
known
interfer
defens
predispos
host
infect
alter
level
conscious
caus
stroke
seizur
drug
intox
anesthesia
alcohol
abus
even
normal
sleep
compromis
epiglott
closur
lead
aspir
oropharyng
microbiota
lower
respiratori
tract
cigarett
smoke
perhap
common
agent
involv
compromis
natur
pulmonari
defens
mechan
disrupt
mucociliari
transport
well
alter
macrophag
band
tlymphocyt
function
alcohol
impair
cough
epiglott
reflex
also
associ
increas
colon
oropharynx
aerob
gramneg
bacilli
decreas
mobil
neutrophil
abnorm
phagocyt
oxid
metabol
abnorm
chemotaxi
alcohol
effect
block
tnf
respons
endotoxin
decreas
recruit
neutrophil
lung
furthermor
alcohol
enhanc
monocyt
product
cytokin
antiinflammatori
properti
infect
mycoplasma
pneumonia
haemophilu
influenza
may
interfer
normal
ciliari
function
virus
may
actual
special
note
need
made
relationship
pneumonia
patient
copd
although
wellcontrol
studi
lack
appear
patient
copd
increas
incid
pneumonia
howev
tracheobronchi
tree
often
colon
streptococcu
pneumonia
h
influenza
difficult
distinguish
clearli
colon
infect
mani
studi
although
organ
play
import
role
etiolog
agent
pneumonia
patient
popul
clinic
studi
carri
recogn
less
common
pathogen
also
play
signific
role
caus
diseas
role
moraxella
catarrhali
legionella
chlamydia
aerob
gramneg
rod
includ
p
aeruginosa
establish
cystic
fibrosi
commonli
associ
pseudomona
staphylococc
pulmonari
infect
burkholderia
spp
stenotrophomona
spp
achromobact
xylosoxidan
atyp
mycobacteria
also
import
pulmonari
pathogen
set
pulmonari
alveolar
proteinosi
associ
nocardia
infect
patient
infect
hiv
high
risk
develop
pulmonari
infect
although
incid
pneumonia
decreas
notabl
develop
world
advent
highli
activ
antiretrovir
therapi
pneumonia
remain
common
hiv
complic
princip
risk
factor
pneumonia
popul
includ
low
current
count
nadir
count
inject
drug
use
smoke
increas
age
lack
highli
activ
antiretrovir
therapi
antipneumocysti
prophylaxi
consid
etiolog
pulmonari
infect
patient
infect
hiv
geograph
exposur
demograph
characterist
patient
degre
immun
suppress
need
consid
develop
highli
activ
antiretrovir
therapi
haart
effect
prophylact
strategi
incid
pneumocysti
jirovecii
pneumonia
patient
aid
decreas
less
per
patientyear
predominantli
seen
individu
count
less
either
unawar
hiv
infect
receiv
care
bacteri
pneumonia
signific
complic
hivinfect
individu
preantiretrovir
era
incid
seen
gener
popul
incid
invas
pneumococc
diseas
higher
hivinfect
patient
nonhivinfect
control
incid
infect
notabl
decreas
although
remain
high
risk
patient
treatment
incid
pneumonia
due
p
aeruginosa
aureu
also
notabl
higher
hivinfect
patient
although
rel
less
common
develop
world
develop
countri
mycobacterium
tuberculosi
view
major
pulmonari
pathogen
patient
aid
use
haart
led
decreas
incid
aid
overal
import
pulmonari
pathogen
remain
sever
immunosuppress
hiv
popul
fungal
infect
play
major
role
depend
patient
exposur
histori
cryptococcosi
histoplasmosi
blastomycosi
coccidioidomycosi
consid
patient
infect
hiv
relationship
degre
immun
suppress
use
count
marker
specif
etiolog
pneumonia
deserv
emphasi
bacteri
pneumonia
pulmonari
tuberculosi
usual
occur
count
less
increas
risk
count
fall
pneumocysti
dissemin
tuberculosi
associ
count
dissemin
nontubercul
mycobacteri
fungal
infect
occur
count
less
pulmonari
infect
hivinfect
patient
discuss
detail
chapter
pneumonia
develop
hospit
patient
often
involv
enterobacteriacea
p
aeruginosa
aureu
organ
unusu
communityacquir
diseas
pneumonia
older
adult
especi
bedridden
chronic
diseas
believ
often
associ
gramneg
bacilli
pneumonia
younger
popul
associ
remain
unclear
gener
elderli
patient
frequent
infect
due
pneumonia
nontyp
strain
h
influenza
catarrhali
aspir
pneumonia
recent
recogn
patient
outpati
contact
health
care
system
develop
pneumonia
etiolog
vari
includ
malign
lymphoma
chronic
lymphocyt
leukemia
multipl
myeloma
infect
aid
iatrogen
caus
immun
suppress
associ
solidorgan
marrow
transplant
cancer
chemotherapi
highdos
corticosteroid
treatment
tnf
inhibitor
underli
respiratori
tract
disord
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
adultonset
cystic
fibrosi
bronchopulmonari
sequestr
tracheobronchomegali
may
present
pneumonia
bronchial
obstruct
due
intrins
compress
adenocarcinoma
extrins
compress
lymphadenopathi
due
sarcoidosi
malign
also
associ
recurr
episod
pneumonia
underli
diseas
predispos
aspir
lead
increas
incid
pneumonia
may
associ
gastrointestin
diseas
tracheoesophag
fistula
esophag
diverticula
esophag
reflux
esophag
strictur
neuromuscular
disord
myasthenia
gravi
dementia
amyotroph
later
sclerosi
cancer
head
neck
system
ill
includ
chronic
renal
failur
diabet
sickl
cell
diseas
associ
pneumonia
histori
attempt
defin
symptom
consist
diagnosi
pneumonia
clinic
set
pneumonia
take
place
defect
host
defens
could
predispos
develop
pneumonia
possibl
exposur
specif
pathogen
respiratori
symptom
commonli
encount
primari
care
practic
usual
associ
pneumonia
analysi
data
year
found
million
primari
care
visit
year
cough
visit
link
pneumonia
therefor
seriou
effort
made
differenti
pneumonia
clinic
entiti
may
confus
predomin
clinic
find
pneumonia
relat
respiratori
tract
sought
includ
cough
sputum
product
dyspnea
chest
pain
fever
also
recogn
nonrespiratori
symptom
commonli
present
includ
fatigu
sweat
headach
nausea
myalgia
occasion
abdomin
pain
diarrhea
increas
age
respiratori
nonrespiratori
symptom
pneumonia
becom
less
frequent
unfortun
symptom
present
elucid
care
histori
may
alway
abl
distinguish
pneumonia
respiratori
problem
specif
etiolog
agent
pneumonia
associ
certain
underli
diseas
patient
popul
pneumonia
due
pneumonia
occur
often
younger
peopl
may
caus
pneumonia
older
patient
sever
enough
requir
hospit
gramneg
bacteri
pneumonia
tend
occur
older
adult
especi
debilit
comorbid
diseas
ill
enough
requir
manag
intens
care
unit
icu
tuberculosi
suspect
homeless
infect
hiv
come
develop
countri
tuberculosi
preval
expos
other
diseas
staphylococc
pneumonia
classic
note
epidem
influenza
past
year
methicillinresist
staphylococcu
aureu
mrsa
grown
import
caus
ventilatorassoci
pneumonia
vap
addit
sinc
late
strain
communityacquir
mrsa
emerg
infrequ
import
caus
cap
pneumonia
note
occur
increas
frequenc
patient
varieti
underli
disord
congest
heart
failur
diabet
alcohol
copd
one
seri
patient
pneumonia
found
underli
diseas
certain
lifestyl
factor
also
associ
increas
risk
pneumonia
includ
cigarett
smoke
alcohol
use
especi
male
contact
children
pet
live
household
peopl
viral
upper
respiratori
tract
infect
predispos
pneumonia
may
associ
sever
diseas
recent
dental
manipul
sed
overdos
seizur
alcohol
loss
conscious
reason
rais
suspicion
anaerob
infect
caus
aspir
oral
content
hydrat
intravascular
fluid
volum
puls
usual
increas
beatsmin
everi
degre
centigrad
temperatur
elev
pulsetemperatur
deficit
eg
rel
bradycardia
amount
fever
suggest
viral
infect
mycoplasm
infect
chlamydi
infect
tularemia
infect
legionella
cyanosi
rapid
respiratori
rate
use
accessori
muscl
respir
sternal
retract
nasal
flare
suggest
seriou
respiratori
compromis
cutan
abscess
track
mark
inject
drug
use
may
signal
sourc
bacteremia
subsequ
pneumonia
via
hematogen
spread
bullou
myring
infrequ
signific
find
mycoplasm
pneumonia
presenc
poor
dentit
suggest
mix
infect
due
aspir
anaerob
aerob
colon
oropharynx
although
edentul
patient
may
develop
anaerob
pneumonia
result
aspir
uncommon
examin
thorax
may
reveal
splint
inspiratori
lag
side
lesion
suggest
bacteri
pneumonia
earli
diseas
process
definit
sign
pulmonari
involv
may
lack
may
manifest
fine
rale
chest
examin
may
reveal
earli
sign
pneumonia
even
though
chest
radiograph
normal
evid
consolid
dull
percuss
bronchial
breath
sound
e
chang
highli
suggest
bacteri
infect
may
absent
two
third
patient
ill
enough
hospit
may
absent
often
patient
treat
outpati
patient
mycoplasm
viral
infect
may
exhibit
abnorm
physic
examin
despit
presenc
impress
infiltr
chest
radiograph
overal
use
histori
physic
examin
detect
presenc
pneumonia
question
probabl
detect
pneumonia
vari
patient
popul
preval
pneumonia
popul
threshold
valu
defin
vital
sign
abnorm
abil
clinician
detect
abnorm
physic
find
howev
great
deal
interobserv
variat
shown
exist
one
seri
three
examin
see
patient
could
consist
agre
physic
examin
find
diagnosi
pneumonia
could
made
sensit
specif
rare
find
egophoni
asymmetr
chest
movement
high
predict
valu
pneumonia
occur
infrequ
limit
util
sever
studi
assess
util
clinic
predict
rule
presenc
absenc
pneumonia
base
multipl
physic
find
absenc
vital
sign
abnorm
ie
respiratori
rate
breathsmin
heart
rate
beatsminut
temperatur
c
f
associ
less
chanc
patient
pneumonia
assum
pneumonia
preval
popul
studi
contrast
constel
cough
fever
tachycardia
decreas
breath
sound
crackl
rais
possibl
pneumonia
present
therefor
although
variabl
nondefinit
complet
histori
physic
examin
may
extrem
help
guid
workup
pneumonia
clinic
featur
deriv
care
histori
physic
examin
confirm
radiograph
imag
chest
show
pulmonari
infiltr
suggest
presenc
pneumonia
role
microbiolog
test
identifi
specif
caus
import
although
controversi
element
care
empir
antibiot
regimen
success
therapi
cap
especi
mild
moder
case
studi
compar
empir
therapi
laboratoryguid
pathogendirect
care
shown
differ
efficaci
although
increas
side
effect
note
patient
receiv
empir
therapi
effort
determin
specif
caus
cap
justifi
fact
may
enabl
clinician
narrow
antibiot
spectrum
use
fewer
agent
therebi
decreas
exposur
patient
potenti
side
effect
potenti
reduc
develop
resist
may
aid
specif
antibiot
choic
individu
patient
depend
specif
epidemiolog
infect
specif
resist
pattern
local
may
identifi
pathogen
usual
suspect
therefor
agent
may
seen
cap
nosocomi
pneumonia
increas
import
mrsa
aerob
gramneg
rod
includ
p
aeruginosa
mix
aerobicanaerob
organ
due
aspir
associ
new
syndrom
health
careassoci
pneumonia
hcap
see
discuss
pneumonia
syndrom
import
aspect
patient
histori
may
suggest
specif
potenti
infecti
agent
includ
occup
anim
travel
histori
tabl
care
obtain
histori
may
also
suggest
presenc
noninfecti
pulmonari
diseas
tumor
sarcoidosi
granulomatosi
polyangi
previous
known
wegen
granulomatosi
pulmonari
emboli
may
masquerad
pneumonia
patient
pneumonia
look
ill
sometim
acut
may
breath
accessori
muscl
elderli
patient
may
appear
apathet
fever
report
present
patient
pneumonia
may
sustain
remitt
time
hectic
fever
pattern
per
se
howev
use
establish
specif
diagnosi
oral
temperatur
assess
avoid
reduc
error
caus
rapid
mouth
breath
record
postur
chang
blood
pressur
puls
rate
use
assess
gram
stain
detect
h
influenza
usual
less
pneumonia
report
staphylococci
appear
gramposit
cocci
tetrad
grapelik
cluster
see
fig
organ
mix
morpholog
characterist
anaerob
infect
bacteria
seen
legionnair
diseas
mycoplasma
pneumonia
viral
pneumonia
examin
induc
sputum
obtain
patient
undergo
nebul
treatment
salin
solut
use
mean
diagnos
pneumocysti
pneumonia
patient
aid
use
commerci
avail
monoclon
antibodi
giemsa
gomori
methenamin
usual
cover
empir
therapi
broader
scale
identifi
specif
caus
may
help
defin
new
agent
trend
antibiot
resist
establish
agent
epidemiolog
infecti
outbreak
combin
use
standard
microbiolog
test
conjunct
nucleic
amplif
assay
defin
etiolog
cap
case
recent
guidelin
infecti
diseas
societi
america
american
thorac
societi
idsaat
suggest
diagnost
test
whenev
result
like
chang
individu
antibiot
manag
patient
diagnost
yield
thought
greatest
microscop
examin
cultur
expector
sputum
remain
mainstay
laboratori
evalu
pneumonia
despit
ongo
controversi
concern
sensit
specif
patient
admit
hospit
cap
abl
produc
sputum
sampl
may
judg
inadequ
studi
oropharyng
contamin
mani
patient
receiv
antibiot
studi
carri
drastic
reduc
diagnost
yield
varieti
organ
detect
gram
stain
includ
legionella
spp
mycoplasma
spp
chlamydia
spp
howev
patient
produc
sputum
adequ
qualiti
examin
minim
oropharyng
contamin
receiv
prior
antibiot
diagnost
yield
sputum
gram
stain
report
small
fraction
patient
bacterem
pneumonia
pneumonia
despit
pitfal
sputum
gram
stain
noninvas
perform
risk
patient
right
circumst
may
aid
diagnosi
choic
empir
therapi
patient
cap
examin
sputum
includ
observ
color
amount
consist
odor
specimen
mucopurul
sputum
commonli
found
bacteri
pneumonia
bronchiti
howev
sputum
similar
natur
describ
one
third
one
half
patient
mycoplasm
adenoviru
infect
scant
wateri
sputum
often
note
atyp
pneumonia
rusti
sputum
suggest
alveolar
involv
commonli
although
sole
associ
pneumococc
pneumonia
dark
red
mucoid
sputum
currantjelli
sputum
suggest
friedland
pneumonia
caus
encapsul
klebsiella
pneumonia
fig
foulsmel
sputum
associ
mix
anaerob
infect
commonli
seen
aspir
maxim
diagnost
yield
sputum
examin
sampl
minim
oropharyng
contamin
review
although
definit
guidelin
number
neutrophil
epitheli
cell
quantit
low
power
examin
reserv
sampl
contain
neutrophil
fewer
epitheli
cell
sampl
epitheli
cell
fewer
neutrophil
usual
nondiagnost
discard
morpholog
stain
characterist
bacteria
seen
record
estim
made
predomin
organ
fig
bacteri
predomin
exist
note
well
appropri
clinic
set
predomin
gramposit
lancetshap
diplococci
suggest
pneumococc
infect
see
fig
strict
criteria
gram
stain
posit
use
find
predomin
organ
gramposit
lancetshap
diplococci
per
oil
immers
field
specif
gram
stain
identifi
pneumococci
shown
sensit
pneumococci
may
part
nasopharyng
microbiota
healthi
adult
often
colon
lower
airway
patient
chronic
bronchiti
identif
organ
mean
caus
diseas
howev
experi
larg
number
pneumococci
necessari
produc
posit
gram
stain
unusu
carrier
microscop
sputum
examin
help
identifi
organ
pneumococci
find
small
gramneg
coccobacillari
organ
sputum
gram
stain
characterist
h
influenza
see
fig
howev
sensit
sputum
sputum
cultur
posit
proven
h
influenza
pneumonia
pneumonia
h
influenza
rel
fastidi
sensit
cultur
decreas
prior
use
antibiot
delay
transport
specimen
clinic
microbiolog
laboratori
beyond
concern
test
sensit
sputum
cultur
frequent
shown
yield
bacteri
speci
invas
method
obtain
respiratori
tract
secret
lack
correl
find
sputum
cultur
find
blood
cultur
serolog
studi
observ
sever
key
paramet
identifi
effort
maxim
diagnost
yield
sputum
cultur
procur
adequ
sputum
sampl
essenti
first
step
increas
number
epitheli
cell
decreas
number
neutrophil
increas
amount
oropharyng
contamin
present
indic
isol
bacteri
speci
presenc
alveolar
macrophag
alter
bacteriolog
find
substanti
number
epitheli
cell
present
indic
otherwis
adequ
sampl
sputum
contamin
oropharyng
content
therebi
render
nondiagnost
type
initi
screen
prove
help
differenti
adequ
sputum
sampl
saliva
therebi
increas
diagnost
yield
sputum
cultur
cultur
sputum
delay
isol
pneumococci
less
like
overgrowth
oropharyng
microbiota
rapid
process
sampl
therefor
anoth
import
factor
lead
higher
diagnost
yield
report
suggest
adequ
sputum
sampl
prompt
cultur
specimen
diagnost
yield
sputum
cultur
may
improv
antigen
detect
respiratori
secret
use
decad
tri
maxim
diagnost
yield
sputum
especi
infect
caus
pneumonia
pneumocysti
legionella
pneumophila
varieti
respiratori
virus
direct
fluoresc
antibodi
assay
l
pneumophila
pneumocysti
jirovecii
commonli
util
sensit
legionella
pneumocysti
sensit
pneumocysti
may
less
patient
caus
immunosuppress
hiv
diseas
specif
approxim
report
assay
pathogen
nonpneumophila
pneumophila
nonserogroup
strain
legionella
may
miss
assay
test
need
perform
experienc
technologist
organ
chlamydia
problem
colon
versu
infect
vari
sensit
crossreact
nonpathogen
limit
use
studi
detect
microbi
nucleic
acid
respiratori
tract
secret
nasopharyng
sputum
remain
area
ongo
studi
nucleic
acid
amplif
assay
especi
polymeras
chain
reaction
pcr
particularli
attract
capabl
detect
minut
amount
materi
potenti
pathogen
appear
greatli
influenc
prior
antibiot
therapi
perform
quickli
wherea
varieti
pcr
techniqu
silver
toluidin
blue
stain
led
diagnosi
case
make
aggress
diagnost
procedur
unnecessari
special
sputum
stain
techniqu
import
identifi
organ
mycobacteria
fig
sputum
cultur
mean
diagnos
pneumonia
controversi
sputum
gram
stain
patient
pneumonia
produc
sputum
even
studi
patient
bacterem
pneumococc
pneumonia
found
sputum
cultur
posit
rate
vari
similarli
use
diagnosi
atyp
pneumonia
includ
caus
legionella
speci
pneumonia
falseneg
find
seen
patient
may
reflect
fact
bacteri
count
may
differ
area
infect
lung
versu
noninfect
adjac
area
make
sampl
site
import
consider
possibl
explan
includ
prior
antibiot
use
techniqu
problem
case
earli
stage
pneumonia
bacteri
number
yet
high
enough
reach
breakpoint
procedur
bronchoscopi
bal
particularli
valu
immunocompromis
host
includ
patient
aid
patient
aid
diagnost
yield
pneumocysti
pneumonia
report
excel
yield
also
note
detect
cytomegaloviru
patient
aid
well
bone
marrow
solidorgan
transplant
recipi
although
detect
agent
alon
prove
caus
pneumonia
high
degre
immunosuppress
patient
popul
permit
high
level
pathogen
flourish
make
detect
easier
bal
also
shown
use
diagnosi
pulmonari
tuberculosi
fungal
infect
cultur
bal
materi
sensit
approxim
tuberculosi
even
set
neg
cultur
expector
sputum
gastric
aspir
sampl
use
strict
diagnost
definit
perform
pcr
galactomannan
assay
bal
approxim
sensit
specif
invas
pulmonari
aspergillosi
bronchoscopi
calcofluor
stain
fungal
cultur
also
help
diagnosi
pulmonari
histoplasmosi
cryptococcosi
coccidioidomycosi
bronchoscopi
bal
use
wide
patient
ventilatorassoci
pneumonia
vap
bacteriolog
strategi
recommend
idsaat
guidelin
vap
recommend
bronchoscopi
bal
endobronchi
aspir
establish
presenc
absenc
pulmonari
infect
well
determin
specif
etiolog
prospect
multicent
trial
found
use
bronchoscopi
bal
quantit
cultur
improv
clinic
outcom
compar
nonquantit
cultur
endotrach
secret
bronchoscopi
without
risk
induc
respiratori
failur
need
mechan
ventil
hypoxem
patient
risk
bleed
use
protect
brush
cathet
transbronchi
biopsi
well
lesser
risk
pneumothorax
patient
gramneg
pneumonia
sepsislik
pictur
increas
temperatur
decreas
mean
arteri
pressur
may
follow
procedur
usual
consid
patient
cap
unless
infect
sever
unresolv
clear
failur
antibiot
therapi
encount
suggest
occult
process
concern
minor
obstruct
lesion
foreign
bodi
seen
diagnost
imag
varieti
less
invas
techniqu
use
attempt
determin
caus
pneumonia
without
resort
bronchoscopi
blind
endotrach
suction
quantit
cultur
compar
favor
bronchoscop
procedur
investig
vap
studi
threshold
greater
colonyform
unit
cfu
ml
sensit
predict
vap
compar
lavag
protect
brush
procedur
although
specif
somewhat
lower
furthermor
differ
mortal
length
icu
stay
durat
mechan
ventil
note
quantit
endotrach
cultur
use
sole
mean
diagnosi
compar
bal
protect
specimen
brush
other
report
falseneg
rate
mani
organ
isol
endotrach
suction
brush
addit
set
vap
concern
remain
sampl
error
well
potenti
differ
pathogen
differ
lung
segment
present
none
techniqu
shown
increas
accuraci
diagnos
vap
studi
clinic
outcom
found
mortal
vap
unchang
independ
whether
bronchoscop
nonbronchoscop
procedur
use
diagnosi
describ
us
food
drug
administr
fda
licens
assay
exist
tuberculosi
legionella
spp
respiratori
virus
assay
commonli
encount
organ
pneumonia
h
influenza
mycoplasma
chlamydia
spp
develop
lack
standard
difficulti
determin
true
infect
colon
remain
problemat
falseneg
result
report
presenc
natur
inhibitor
although
pcr
assay
use
detect
p
jirovecii
publish
studi
detect
posit
result
set
neg
cultur
absenc
clinic
featur
infect
pcr
techniqu
use
identifi
dna
tuberculosi
sputum
lavag
fluid
sensit
seen
patient
acidfast
bacilli
afb
smear
posit
result
report
patient
afb
smear
neg
specif
high
note
howev
pcr
assay
may
remain
persist
posit
patient
recent
treat
tuberculosi
appar
activ
diseas
sever
individu
pathogen
multiplex
realtim
pcr
assay
system
becom
commerci
avail
detect
commun
respiratori
virus
test
system
differ
viral
pathogen
detect
inhous
assay
select
pathogen
frequent
fda
approv
avail
assay
detect
influenza
influenza
b
parainfluenza
virus
respiratori
syncyti
viru
rsv
human
metapneumoviru
coronavirus
rhinovirus
bocaviru
respiratori
secret
high
sensit
specif
presenc
viral
nucleic
acid
howev
unclear
posit
result
indic
upper
rather
lower
respiratori
tract
infect
colon
true
infect
lung
even
presenc
infecti
viru
particl
overal
molecular
assay
clear
util
research
purpos
howev
remain
expens
although
may
benefit
manag
sever
ill
hospit
patient
select
clinic
set
costeffect
gener
manag
acut
pneumonia
yet
defin
although
sputum
examin
alway
includ
initi
evalu
patient
pneumonia
may
inadequ
presumpt
diagnosi
particularli
immunocompromis
host
patient
mechan
ventil
broader
rang
potenti
pathogen
fiberopt
bronchoscopi
allow
collect
lower
respiratori
tract
cultur
use
protect
brush
cathet
perform
either
bronchoalveolar
lavag
bal
transbronchi
biopsi
bal
segment
lung
wash
steril
fluid
sampl
approxim
million
alveoli
consequ
examin
larger
segment
lung
either
protect
specimen
brush
transbronchi
biopsi
use
protect
brush
cathet
quantit
cultur
materi
obtain
procedur
minim
problem
oropharyng
contamin
help
differenti
colon
true
infect
approxim
organ
per
millilit
present
lung
tissu
involv
pneumonia
account
dilut
sampl
bacteri
count
use
breakpoint
determin
clinic
signific
isol
studi
prospect
earli
cours
cap
bronchoscopi
yield
diagnosi
approxim
patient
bronchoscopi
protect
specimen
brush
shown
sensit
high
low
specif
high
low
diagnosi
bacteri
pneumonia
differ
exclus
inclus
criteria
differ
definit
pneumonia
accept
reject
patient
recent
antibiot
chang
may
explain
differ
result
use
antibiot
markedli
diminish
diagnost
yield
procedur
bacteri
speci
initi
found
protect
specimen
brush
undetect
hour
antibiot
therapi
major
organ
found
resist
antibiot
given
may
role
infect
howev
patient
ongo
pneumonia
despit
antibiot
therapi
bronchoscopi
protect
specimen
brush
pick
resist
organ
may
play
role
infect
bal
also
complic
pleural
effus
posit
cultur
result
case
make
thoracentesi
cultur
fluid
valuabl
mean
make
etiolog
diagnosi
underli
pneumonia
diagnost
tool
proven
use
identifi
organ
associ
pleural
effus
pcr
technolog
use
detect
tuberculosi
well
defin
etiolog
cultureneg
case
adenosin
deaminas
enzym
associ
lymphocyt
may
also
use
detect
tuberculosi
sensit
specif
blood
cultur
serolog
studi
urin
studi
includ
antigen
detect
blood
cultur
posit
patient
hospit
cap
frequenc
posit
result
increas
sever
ill
recent
studi
suggest
posit
blood
cultur
add
littl
manag
patient
hospit
cap
predict
increas
mortal
howev
presenc
trueposit
blood
cultur
highli
specif
may
help
narrow
antibiot
use
may
identifi
presenc
unusu
organ
would
adequ
cover
routin
empir
antibiot
coverag
recent
work
shown
sever
clinic
featur
use
predict
patient
higher
likelihood
bacteremia
particular
patient
two
find
chronic
liver
diseas
pleurit
pain
tachycardia
tachypnea
systol
hypotens
absenc
prior
antibiot
therapi
least
incid
bacteremia
bacteremia
incid
four
find
clear
blood
cultur
obtain
antibiot
administr
patient
cap
ill
enough
hospit
two
featur
well
patient
immunocompromis
admit
hcap
acquir
pneumonia
hospit
idsa
at
also
recommend
blood
cultur
patient
admit
icu
cavitari
lesion
leukopenia
activ
alcohol
abus
asplenia
posit
pneumococc
urinari
antigen
pleural
effus
furthermor
etiolog
pneumonia
alway
determin
assess
clinic
respons
initi
therapi
import
blood
cultur
obtain
patient
respond
antibiot
therapi
varieti
assay
util
detect
pathogen
difficult
isol
use
routin
cultur
techniqu
serolog
assay
use
diagnos
infect
caus
legionella
spp
pneumonia
chlamydia
spp
coxiella
burnetii
sensit
specif
assay
vari
overal
use
make
rapid
diagnosi
limit
center
diseas
control
prevent
cdc
laboratori
centr
diseas
control
lcdc
establish
diagnost
standard
chlamydia
assay
microimmunofluoresc
mif
serum
chlamydi
antigen
recommend
although
enzym
immunoassay
also
avail
may
sensit
specif
mif
assay
igm
titer
greater
fourfold
rise
igg
valu
use
defin
posit
use
singl
igg
valu
view
definit
test
present
assay
show
daytoday
variat
suggest
acut
convalesc
titer
assay
time
fourfold
rise
igg
rather
singl
clinic
titer
accept
posit
test
pneumonia
although
elev
igm
titer
suggest
recent
infect
reinfect
mycoplasma
occur
frequent
rise
igm
may
alway
seen
cold
agglutinin
may
elev
infect
pneumonia
titer
greater
equal
suggest
pneumonia
infect
mycoplasm
chlamydi
infect
nucleic
amplif
technolog
examin
altern
diagnost
modal
pneumonia
produc
varieti
antigen
surfac
marker
type
speci
specif
although
antigen
antibodi
detect
method
serum
studi
none
becom
clinic
signific
pcr
techniqu
appli
whole
blood
detect
pneumococci
assay
remain
experiment
serum
assay
cryptococc
capsular
antigen
rel
low
sensit
cryptococc
pneumonia
highli
specif
benefit
manag
immunocompromis
patient
well
direct
mean
obtain
diagnost
materi
patient
pneumonia
includ
percutan
lung
aspir
transbronchi
lung
biopsi
videoassist
thoracoscopi
open
lung
biopsi
procedur
usual
reserv
case
sever
pneumonia
impair
host
pediatr
popul
sputum
routin
avail
biopsi
procedur
rare
indic
previous
well
patient
acut
pneumonia
indic
use
invas
procedur
remain
controversi
blind
lung
aspir
provid
diagnost
yield
adult
children
diffus
lung
infiltr
although
falseneg
rate
report
comput
tomograph
ct
guid
percutan
lung
aspir
shown
effect
diagnos
focal
fungal
infect
transplant
popul
bleed
pneumothorax
report
major
complic
procedur
open
lung
biopsi
remain
definit
invas
procedur
make
etiolog
diagnosi
pneumonia
immunosuppress
patient
diagnost
yield
immunocompromis
patient
incid
unexpect
diagnos
lead
chang
treatment
although
clinic
util
seem
significantli
lower
immunocompet
popul
incid
pneumothorax
bleed
usual
less
even
patient
thrombocytopen
characterist
pleural
effus
import
differenti
diagnosi
pulmonari
diseas
discuss
chapter
pleural
effus
parapneumon
effus
occur
hospit
patient
pneumonia
incid
sever
pleural
involv
increas
recent
year
incid
pleural
effus
associ
pneumonia
vari
etiolog
agent
pneumococci
gramneg
bacilli
streptococci
pleural
fluid
cultur
posit
specif
organ
caus
underli
pneumonia
furthermor
analysi
pleural
fluid
may
play
major
role
determin
drainag
necessari
well
differenti
caus
pulmonari
infiltr
may
mimic
bacteri
pneumonia
includ
tuberculosi
tumor
pulmonari
emboli
collagen
vascular
diseas
neutrophil
predomin
cell
type
seen
pleural
space
diagnosi
bacteri
pneumonia
sought
pleural
biopsi
specimen
patient
acut
bacteri
pneumonia
nonspecif
therefor
littl
use
differenti
diagnosi
parapneumon
effus
divid
three
stage
first
stage
exud
stage
cultur
neg
ph
greater
glucos
level
greater
mgdl
lactat
dehydrogenas
level
less
three
time
upper
limit
normal
stage
due
pulmonari
interstiti
fluid
enter
pleural
space
increas
permeabl
capillari
pleura
uncompl
pleural
effus
usual
resolv
therapi
underli
diseas
without
appropri
therapi
pleural
effus
becom
infect
organ
caus
underli
pneumonia
develop
second
stage
fibropurul
stage
stage
associ
posit
microbi
cultur
ph
less
glucos
level
less
mgdl
lactat
dehydrogenas
level
greater
three
time
upper
limit
normal
complic
pleural
effus
requir
drainag
sensit
find
determin
pleural
effus
need
drainag
pleural
fluid
ph
less
usual
occur
chemic
paramet
associ
complic
pleural
effus
develop
ph
use
determin
effus
drain
must
measur
blood
ga
machin
ph
meter
ph
indic
strip
inaccur
left
untreat
fibropurul
pleural
effus
develop
stage
three
effus
thick
pleural
rind
form
restrict
normal
lung
expans
empyema
defin
pu
pleural
space
repres
late
manifest
complic
pleural
effus
presenc
empyema
mandat
drain
pleural
space
worsen
infect
defin
precis
caus
pneumonia
clinic
import
chest
radiographi
play
critic
role
diagnosi
pneumonia
mani
repres
gold
standard
make
clinic
diagnosi
differenti
diagnosi
respiratori
complaint
abnorm
physic
find
includ
upper
lower
respiratori
tract
infect
well
array
noninfecti
entiti
demonstr
abnorm
chest
radiograph
pulmonari
infiltr
consist
pneumonia
differenti
patient
popul
may
benefit
antibiot
therapi
popul
overus
antibiot
therapi
upper
respiratori
tract
infect
document
may
contribut
grow
problem
antibiot
resist
identifi
patient
realli
receiv
antibiot
therapi
clearli
import
chest
radiograph
readili
avail
reason
reliabl
despit
interobserv
variabl
obtain
patient
suspect
pneumonia
extent
natur
radiograph
abnorm
may
defin
patient
serious
ill
may
need
close
monitor
pattern
infiltr
found
chest
radiograph
patient
pneumonia
usual
help
make
specif
etiolog
diagnosi
fig
b
howev
certain
featur
may
diagnost
aid
lobar
consolid
cavit
larg
pleural
effus
support
bacteri
caus
fig
lobar
pneumonia
pneumococc
although
pneumococc
pneumonia
necessarili
lobar
bilater
diffus
involv
note
pneumocysti
pneumonia
legionella
pneumonia
primari
viral
pneumonia
suspect
staphylococc
pneumonia
may
result
infect
metastas
primari
focu
unrel
lung
case
multipl
nodular
infiltr
throughout
lung
may
seen
staphylococci
may
caus
mark
necrosi
lung
tissu
illdefin
thinwal
caviti
pneumatocel
bronchopleur
fistula
empyema
especi
children
fig
aureu
produc
pantonvalentin
leukocidin
whether
methicillin
resist
associ
necrot
pneumonia
multilobar
cavitari
lesion
frequent
associ
pleural
effus
empyema
although
pneumatocel
diagnost
signific
find
staphylococc
pneumonia
may
seen
pneumonia
caus
includ
k
pneumonia
h
influenza
pneumonia
rare
pneumocysti
pulmonari
infect
due
pseudomona
may
cavit
pseudomona
gramneg
bacilli
commonli
caus
lower
lobe
pneumonia
aspir
pneumonia
consid
along
gramneg
staphylococc
pneumonia
sourc
necrot
pneumonia
cavit
empyema
aspir
pneumonia
commonli
involv
either
superior
segment
basilar
segment
either
lower
lobe
posterior
segment
upper
lobe
depend
whether
aspir
occur
depend
upright
posit
chronic
aspir
commonli
result
bilater
lower
lobe
pneumonia
although
may
involv
one
side
viral
infect
lower
airway
involv
respiratori
epithelium
parenchyma
adjac
termin
respiratori
bronchiol
diffus
hemorrhag
congest
alveolar
septa
may
occur
well
radiograph
concomit
patholog
find
usual
involv
patchi
area
peribronchi
groundglass
opac
airspac
consolid
poorli
defin
small
nodul
diffus
local
involv
interstiti
alveolar
pattern
note
fig
littl
radiolog
distinct
variou
viral
caus
pneumonia
influenza
pneumonia
associ
poorli
defin
patchi
airspac
consolid
rapid
confluenc
varicella
pneumonia
usual
involv
peribronchi
involv
nodular
infiltr
adenoviru
herp
simplex
viru
cytomegaloviru
common
immunocompromis
host
may
associ
diffus
bilater
bronchopneumonia
area
overinfl
atelectasi
nodular
opac
lobar
subsegment
consolid
mimick
bacteri
pneumonia
may
also
seen
patient
infect
adenoviru
herp
simplex
viru
hantaviru
pneumonia
usual
present
interstiti
edema
may
progress
consolid
repres
pulmonari
capillari
leak
syndrom
immunocompet
individu
suspect
infect
cryptococcu
gatti
serum
assay
compon
cell
wall
fungi
except
cryptococcu
spp
zygomycet
high
specif
invas
fungal
infect
use
detect
invas
pulmonari
aspergillosi
immunocompromis
host
well
detect
pneumonia
due
endem
fungi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
patient
appropri
geograph
exposur
addit
also
compon
cell
wall
p
jirovecii
serum
assay
sensit
specif
pneumocysti
pneumonia
hivposit
hivneg
immunocompromis
patient
varieti
cytokin
releas
circul
result
infect
evid
suggest
biomark
may
use
adjunct
diagnos
pneumonia
predict
sever
diseas
calcitonin
famili
gene
product
especi
procalcitonin
creactiv
protein
solubl
trigger
receptor
express
myeloid
cell
marker
often
associ
pneumonia
procalcitonin
appear
earliest
marker
appear
cours
infect
clinic
trial
found
presenc
elev
procalcitonin
level
use
identifi
patient
requir
treatment
pneumonia
base
whether
level
fall
long
antibiot
continu
without
increas
risk
advers
outcom
procalcitonin
also
use
gaug
pneumoniarel
mortal
creactiv
protein
acutephas
reactant
produc
liver
respons
varieti
stimuli
includ
infect
normal
valu
less
mgl
unusu
patient
pneumonia
use
exclud
diagnosi
level
mgl
greater
suggest
diagnosi
pneumonia
associ
increas
mortal
greater
likelihood
need
ventil
vasopressor
support
ie
sever
pneumonia
compar
trial
creactiv
protein
appear
better
abil
defin
infect
procalcitonin
clinic
sever
although
definit
studi
lack
cytokin
studi
includ
correl
pneumonia
appear
less
consist
cortisol
level
also
shown
predict
sever
pneumonia
chanc
surviv
although
clinic
trial
procalcitonin
shown
reduct
antibiot
cost
signific
expens
perform
biomark
assay
largescal
random
studi
costeffect
lack
thu
role
diagnosi
sever
assess
pneumonia
clearli
defin
antigen
detect
urin
rather
blood
sputum
becom
success
mean
detect
import
pulmonari
pathogen
solubl
l
pneumophila
antigen
detect
urin
use
commerci
avail
enzym
immunoassay
although
use
detect
l
pneumophila
serogroup
assay
offer
advantag
rapid
noninvas
sensit
specif
estim
addit
rel
limit
assay
antigenuria
may
persist
week
month
therapi
immunochromatograph
membran
test
develop
detect
c
polysaccharid
cell
wall
antigen
found
pneumonia
urin
patient
pneumonia
binax
report
extrem
use
mean
diagnos
pneumococc
pneumonia
use
varieti
standard
diagnost
test
control
overal
sensit
specif
posit
predict
valu
note
sensit
gener
high
bacteremia
episod
yield
increas
slightli
concentr
urin
test
affect
prior
use
antibiot
potenti
problem
urinari
antigen
assay
includ
weakli
posit
result
caus
nonpneumococc
organ
falseposit
result
children
nasopharyng
carriag
rather
true
infect
posit
result
last
week
infect
resolv
shortfal
test
organ
isol
antibiot
suscept
carri
addit
retrospect
analysi
found
impact
routin
use
test
antibiot
prescrib
practic
patient
suspect
pneumonia
suggest
use
reserv
research
purpos
situat
unresolv
bilater
involv
pleural
effus
common
present
associ
wors
clinic
outcom
sever
acut
respiratori
syndrom
sar
coronaviru
newer
novel
coronaviru
identifi
caus
pneumonia
begin
predominantli
bilater
interstiti
basilar
infiltr
progress
sever
symmetr
airspac
diseas
recent
defin
viral
pulmonari
pathogen
human
metapneumoviru
bocaviru
case
human
metapneumoviru
infect
involv
upper
respiratori
tract
infect
children
pneumonia
adult
describ
multilobar
infiltr
note
case
pleural
effus
uncommon
bocaviru
pneumonia
frequent
report
children
associ
patchi
interstiti
infiltr
similar
found
common
respiratori
viru
infect
mycoplasm
pneumonia
often
manifest
interstiti
pattern
peribronchi
perivascular
distribut
consolid
note
approxim
patient
usual
lower
lobe
consolid
stage
reach
radiolog
differenti
bacteri
mycoplasm
pneumonia
difficult
cavit
rare
although
pleural
effus
may
seen
approxim
case
chlamydia
pneumonia
predominantli
caus
unilobar
diseas
associ
air
bronchogram
legionnair
diseas
may
initi
present
radiograph
pictur
similar
mycoplasm
pneumonia
patchi
interstiti
pneumonia
immunocompromis
host
infect
one
possibl
caus
abnorm
chest
radiograph
chest
ct
one
variat
spiral
ct
highresolut
ct
may
aid
better
defin
question
chest
radiograph
may
help
local
involv
area
lung
guid
biopsi
procedur
ct
scan
also
sensit
defin
parenchym
diseas
icu
set
certain
infect
caus
aspergillu
tuberculosi
pneumocysti
characterist
appear
ct
correct
clinic
set
may
make
invas
procedur
unnecessari
ultrasound
ct
imag
may
sensit
defin
pleural
effus
plain
radiograph
techniqu
perfus
magnet
reson
imag
shown
abl
differenti
pneumonia
copd
pulmonari
emboli
clinic
util
techniqu
remain
defin
fine
nodular
pattern
seen
lower
lobe
howev
unlik
situat
mycoplasm
pneumonia
pneumonia
twolob
involv
commonli
seen
rapid
progress
pleural
effus
also
common
pneumonia
caus
legionella
micdadei
may
present
pulmonari
nodul
either
singl
multipl
well
segment
infiltr
pneumonia
caus
l
pneumophila
rapid
radiolog
progress
diseas
characterist
highresolut
ct
shown
improv
radiograph
character
lung
infect
immunocompet
host
chest
ct
help
evalu
recurr
pneumonia
infect
unrespons
therapi
pneumonia
develop
behind
obstruct
caus
tumor
mass
lung
abscess
may
also
better
defin
ct
routin
chest
radiograph
compar
routin
chest
radiograph
highresolut
ct
detect
lung
abnorm
often
better
job
defin
diseas
upper
lower
lobe
lingula
howev
exposur
radiat
radiat
one
ct
scan
equal
six
seven
chest
radiograph
increas
expens
approxim
seven
time
cost
chest
radiograph
limit
use
initi
radiograph
procedur
furthermor
unclear
abnorm
found
chest
ct
scan
truli
repres
sputum
thick
purul
may
rust
color
sputum
gram
stain
reveal
numer
neutrophil
bacteria
often
singl
organ
predomin
chest
film
show
area
parenchym
involv
usual
alveolarfil
process
moder
hypoxemia
due
ventilationperfus
abnorm
even
rigor
laboratori
evalu
use
definit
definit
probabl
possibl
caus
microbiolog
diagnosi
may
made
case
cap
past
case
acut
cap
caus
pneumonia
wherea
pneumococcu
remain
perhap
import
caus
pneumonia
recent
publish
report
indic
rel
import
diminish
defin
caus
pneumonia
ambulatori
patient
hospit
patient
hypothes
appar
decreas
incid
pneumococc
pneumonia
relat
recognit
newer
pathogen
diminish
use
perform
microbiolog
studi
howev
herd
immun
effect
increas
use
pneumococc
vaccin
children
appear
reduc
incid
pneumococc
diseas
adult
children
sever
pneumococc
infect
includ
pneumonia
associ
prior
splenectomi
due
either
trauma
stage
hodgkin
diseas
abnorm
immunoglobulin
respons
myeloma
lymphoma
hiv
infect
function
asplenia
due
system
lupu
erythematosu
marrow
transplant
estim
case
acut
cap
appear
caus
h
influenza
true
incid
organ
obscur
difficulti
isol
sputum
identifi
sputum
gram
stain
difficulti
distinguish
colon
infect
age
patient
presenc
underli
diseas
present
similar
pneumococc
diseas
although
use
h
influenza
conjug
vaccin
decreas
incid
invas
diseas
caus
h
influenza
type
b
strikingli
increas
incid
invas
diseas
includ
pneumonia
caus
nontyp
strain
one
recent
seri
isol
patient
invas
h
influenza
diseas
nontyp
aureu
account
acut
cap
case
take
increas
import
caus
pneumonia
older
adult
influenza
patient
develop
postinfluenza
pneumonia
usual
younger
less
underli
diseas
patient
cap
although
believ
bacteri
pneumonia
set
influenza
develop
clinic
influenza
studi
pandem
indic
bacteri
coinfect
like
aris
peak
viral
replic
patient
present
averag
day
symptom
onset
elev
white
blood
cell
count
shift
left
physic
sign
pulmonari
consolid
radiograph
evid
focal
parenchym
diseas
develop
sputum
gram
stain
consist
bacteri
pneumonia
aureu
may
also
caus
pneumonia
hematogen
produc
multipl
bilater
round
lesion
frequent
cavit
although
present
characterist
associ
rightsid
endocard
inject
drug
user
also
seen
associ
infect
intravascular
cathet
staphylococc
soft
tissu
infect
note
previous
sinc
late
increas
incid
pneumonia
due
communityassoci
aureu
strain
patient
young
comorbid
usual
present
flulik
ill
high
fever
leukopenia
tachycardia
tachypnea
hemoptysi
rapid
evolut
radiographi
multilobar
diseas
case
appear
associ
aureu
strain
carri
pantonvalentin
leukocidin
toxin
regardless
whether
methicillin
resist
adult
respiratori
distress
syndrom
frequent
complic
case
mortal
rate
occur
aerob
gramneg
bacteria
exclus
h
influenza
mix
aerob
anaerob
infect
caus
remain
case
acut
cap
gramneg
rod
may
caus
anywher
pneumonia
case
klebsiella
pneumonia
p
aeruginosa
enterobact
spp
often
isol
organ
gramneg
bacilli
particularli
import
pathogen
older
adult
nuclear
medicin
procedur
use
detect
pneumonia
procedur
includ
citrat
scan
indium
granulocyt
scan
diethylenetriaminepentaacet
acid
aerosol
clearanc
ffluorodeoxyglucos
positron
emiss
tomographi
procedur
use
patient
aid
defin
presenc
lung
infect
absenc
abnorm
chest
radiograph
patient
aid
diffus
uptak
gallium
usual
seen
pneumocysti
infect
may
also
seen
infect
caus
mycobacterium
aviumintracellular
complex
cytomegaloviru
cryptococcu
neoforman
patient
lymphoma
local
uptak
may
associ
bacteri
diseas
focal
uptak
correspond
lymph
node
area
associ
infect
aviumintracellular
complex
tuberculosi
lymphoma
long
list
bacteri
fungal
viral
protozo
agent
may
caus
pneumonia
initi
evalu
rare
result
specif
etiolog
diagnosi
antibiot
therapi
usual
begun
empir
defin
pneumonia
syndrom
basi
clinic
epidemiolog
radiograph
laboratori
paramet
limit
number
organ
commonli
associ
syndrom
help
clinician
select
ration
empir
therapi
like
organ
involv
mani
syndrom
overlap
sign
symptom
time
make
clear
identif
specif
syndrom
individu
imposs
increas
number
patient
live
longer
vari
comorbid
increas
use
biolog
immunomodul
tnf
inhibitor
expand
contact
variou
aspect
health
care
system
led
wider
array
present
etiolog
agent
strategi
empir
therapi
newli
describ
microbi
agent
recogn
potenti
caus
cap
subgroup
syndrom
gener
descript
cap
may
made
base
patient
age
sever
ill
comorbid
need
hospit
epidemiolog
set
patient
acut
cap
usual
middl
late
peak
incid
diseas
gener
occur
midwint
earli
spring
although
diseas
due
legionella
frequent
summer
still
pneumonia
season
diseas
take
place
throughout
year
patient
one
chronic
underli
diseas
immunosuppress
relat
malign
neutropenia
chronic
use
corticosteroid
myelosuppress
agent
hiv
infect
increasingli
observ
classic
cap
present
sudden
onset
chill
follow
fever
pleurit
chest
pain
cough
produc
mucopurul
sputum
sign
symptom
physic
find
vari
accord
age
patient
therapi
antibiot
present
sever
ill
patient
typic
present
sever
day
symptom
cough
note
patient
product
chest
pain
present
case
chill
hemoptysi
approxim
varieti
nonrespiratori
symptom
associ
pneumonia
includ
fatigu
anorexia
sweat
nausea
respiratori
nonrespiratori
find
occur
less
frequent
older
age
group
physic
examin
reveal
fever
patient
may
seen
less
commonli
older
popul
tachypnea
respiratori
rate
breathsmin
note
patient
may
frequent
seen
older
age
group
tachycardia
puls
rate
beatsmin
note
rale
note
approxim
patient
sign
consolid
combin
physic
find
found
adequ
confirm
diagnosi
pneumonia
commonli
white
blood
cell
count
rang
differenti
cell
count
reveal
increas
number
juvenil
form
leukopenia
may
note
poor
prognost
sign
hematocrit
red
blood
cell
indic
usual
normal
adult
remain
question
part
criteria
diagnosi
true
pneumonia
versu
colon
vari
recent
studi
case
pneumonia
attribut
nonhaemophilu
gramneg
bacilli
although
increas
oropharyng
colon
aerob
gramneg
bacilli
document
older
popul
believ
predisposit
develop
pneumonia
caus
organ
colon
appear
relat
debil
patient
rather
age
factor
report
associ
increas
colon
gramneg
organ
includ
prior
use
antibiot
sever
bronchopulmonari
diseas
decreas
activ
alcohol
incontin
regard
one
recent
studi
appar
aspir
pneumonia
nurs
home
popul
older
year
age
util
protect
bronchoalveolar
lavag
defin
microbiolog
etiolog
identifi
gramneg
bacteria
primari
pathogen
follow
mix
anaerob
older
adult
greater
risk
infect
group
b
streptococci
catarrhali
legionella
speci
although
overal
incid
agent
older
popul
rel
low
legionella
describ
caus
sever
pneumonia
elderli
polymicrobi
infect
pneumonia
due
aspir
note
occur
frequent
older
adult
unclear
agent
caus
atyp
pneumonia
older
popul
seri
suggest
pneumonia
pneumonia
unusu
although
document
investig
signific
caus
pneumonia
lead
hospit
older
adult
clear
signific
variat
relat
differ
epidemiolog
characterist
studi
popul
accuraci
diagnost
method
chlamydia
infect
appear
commonli
older
popul
may
caus
case
pneumonia
although
signific
variat
incid
differ
studi
viral
agent
play
import
role
caus
pneumonia
elderli
although
histor
role
underestim
given
difficulti
cultur
rel
insensit
serolog
test
develop
sensit
nucleic
acid
amplif
test
reversetranscriptas
pcr
assay
role
caus
pneumonia
begun
clearli
defin
recent
studi
suggest
viral
caus
one
third
patient
hospit
pneumonia
significantli
viral
infect
note
older
age
group
median
age
year
influenza
b
rsv
human
metapneumoviru
parainfluenza
viru
coronaviru
frequent
identifi
viral
pathogen
recent
studi
indic
half
patient
viral
pathogen
identifi
concurr
bacteri
infect
multipl
concurr
viral
pathogen
also
seen
rhinovirus
defin
direct
caus
pneumonia
found
patient
sever
pneumococc
diseas
vitro
shown
increas
adher
pneumonia
human
tracheal
epitheli
cell
find
rais
question
whether
virus
play
role
facilit
bacteri
infect
rather
role
true
pulmonari
pathogen
clinic
viral
pneumonia
elderli
differenti
bacteri
pneumonia
clinic
routin
laboratori
radiolog
paramet
bacteri
diseas
sign
viral
pneumonia
may
subtl
may
involv
fever
alter
mental
statu
dyspnea
wheez
product
cough
commonli
observ
myalgia
commonli
found
viral
caus
often
seen
influenza
bronchospasm
wheez
may
commonli
seen
rsv
resid
skill
nurs
facil
repres
import
subpopul
older
adult
risk
pneumonia
pneumonia
report
second
frequent
infect
set
carri
highest
mortal
infect
popul
common
caus
hospit
silent
aspir
major
risk
factor
poor
function
statu
nasogastr
feed
confus
presenc
obstruct
lung
diseas
presenc
tracheostomi
advanc
age
key
modifi
risk
factor
inadequ
oral
care
swallow
difficulti
subtl
present
note
especi
chronic
underli
diseas
bedridden
recent
hospit
pseudomona
infect
suspect
patient
pulmonari
comorbid
recent
hospit
stay
legionella
spp
import
waterrel
pulmonari
pathogen
unit
state
regard
mortal
morbid
import
legionella
spp
caus
pneumonia
vari
greatli
differ
geograph
area
incid
rang
sinc
increas
incid
legionellosi
observ
unit
state
especi
east
coast
although
infect
may
occur
age
age
appear
greatest
risk
presenc
high
fever
c
f
male
sex
previou
therapi
multilobar
involv
rapid
progress
radiograph
abnorm
need
intens
care
gastrointestin
neurolog
abnorm
elev
liver
enzym
level
increas
creatinin
level
associ
legionella
pneumonia
howev
clinic
featur
reliabl
distinguish
legionella
pneumonia
caus
bacteria
moraxella
catarrhali
also
identifi
caus
pneumonia
overal
incid
diseas
caus
bacterium
low
import
pathogen
older
adult
copd
variou
form
immunosuppress
discuss
later
number
addit
pathogen
includ
pneumonia
chlamydia
spp
c
burnetii
commun
respiratori
virus
caus
atyp
pneumonia
syndrom
addit
infrequ
patient
pneumonia
either
sequenti
concurr
due
sever
pathogen
influenza
viru
c
pneumonia
infect
follow
infect
pneumonia
pneumonia
elderli
becom
increasingli
import
clinic
entiti
world
popul
age
pneumonia
one
lead
reason
hospit
older
repres
major
caus
morbid
mortal
seri
pneumonia
repres
lead
caus
death
popul
see
chapter
older
age
pneumonia
predictor
increas
mortal
specif
episod
resolv
sever
year
thereaft
clinic
present
pneumonia
older
adult
especi
year
may
subtler
younger
popul
gradual
onset
symptom
fever
classic
sign
pneumonia
fever
occur
less
commonli
older
adult
temperatur
elev
mute
classic
find
cough
fever
dyspnea
may
absent
half
older
adult
chill
rigor
may
less
frequent
seen
well
tachypnea
respiratori
rate
breathsmin
rale
frequent
find
older
adult
observ
patient
nonrespiratori
symptom
may
major
present
featur
initi
present
older
adult
pneumonia
may
includ
declin
function
statu
weak
subtl
chang
mental
statu
anorexia
abdomin
pain
suggest
nonspecif
present
pneumonia
older
adult
may
result
great
part
preval
dementia
popul
bacteremia
develop
inhospit
complic
death
frequent
older
popul
specif
etiolog
diagnos
made
less
frequent
older
adult
patient
etiolog
agent
defin
absenc
product
cough
common
prior
use
antibiot
may
explain
observ
caus
vari
differ
seri
depend
mean
diagnosi
patient
popul
studi
outpati
vs
institution
older
adult
geograph
locat
gener
caus
cap
older
popul
follow
gener
trend
infect
younger
popul
pneumonia
remain
predomin
organ
account
case
increas
frequenc
aspir
pneumonia
h
influenza
usual
nontyp
strain
frequent
second
common
agent
account
episod
import
aerob
gramneg
bacilli
caus
pneumonia
older
health
care
system
led
blur
distinct
cap
nosocomi
pneumonia
recent
recogn
hcap
repres
distinct
syndrom
hybrid
cap
hospitalacquir
pneumonia
hap
exact
definit
use
studi
vari
gener
defin
pneumonia
develop
patient
hospit
day
within
day
develop
infect
patient
attend
hospit
hemodialysi
clinic
patient
receiv
intraven
antibiot
therapi
wound
care
chemotherapi
home
within
day
develop
infect
resid
longterm
care
facil
nurs
home
aerob
gramneg
bacilli
includ
p
aeruginosa
pneumonia
aureu
includ
mrsa
mix
aerobicanaerob
pathogen
associ
aspir
commonli
report
role
pneumonia
variabl
gener
appear
play
lesser
role
patient
classic
cap
overal
mortal
appear
higher
patient
hcap
cap
gener
compar
hap
clear
whether
due
increas
comorbid
patient
virul
organ
caus
infect
increas
incid
inappropri
antibiot
usag
first
hour
care
combin
factor
late
main
bacteri
caus
pneumonia
defin
hobart
reimann
describ
small
number
patient
clinic
pictur
atyp
episod
began
mild
respiratori
tract
ill
follow
pneumonia
dyspnea
cough
without
sputum
subsequ
investig
shown
syndrom
seen
number
differ
pathogen
pneumonia
c
pneumonia
l
pneumophila
respiratori
virus
signific
agent
chlamydia
psittaci
francisella
tularensi
tuberculosi
c
burnetii
may
also
caus
atyp
pneumonia
patient
aid
pneumocysti
nontubercul
mycobacteria
also
includ
although
seri
report
almost
patient
cap
demonstr
serolog
evid
mycoplasm
chlamydi
pneumonia
seri
suggest
incid
differ
incid
mycoplasm
chlamydi
diseas
differ
studi
may
relat
presenc
epidem
pathogen
studi
period
well
diagnost
methodolog
util
note
earlier
rel
frequenc
pathogen
also
vari
diseas
sever
histor
epidemiolog
clinic
featur
atyp
pneumonia
believ
suffici
distinct
differenti
clearli
caus
cap
clear
differenti
atyp
agent
typic
bacteri
caus
cap
imprecis
pneumonia
may
account
case
cap
highest
percentag
note
patient
well
enough
treat
outpati
sever
studi
perform
north
america
europ
suggest
cyclic
epidem
everi
year
like
occur
children
older
year
adolesc
young
adult
major
case
occur
younger
year
age
although
caus
pneumonia
requir
hospit
older
increas
incid
diseas
true
epidem
document
rel
enclos
popul
young
adult
militari
base
colleg
board
school
although
diseas
sever
may
mild
owe
long
incub
approxim
week
outbreak
quit
prolong
mycoplasm
infect
occur
throughout
year
although
rel
increas
incid
note
late
summer
fall
cours
infect
pneumonia
character
day
symptom
present
true
mani
agent
involv
atyp
pneumonia
classic
form
mycoplasm
infect
present
constitut
symptom
progress
upper
lower
respiratori
tract
sore
throat
often
initi
find
one
third
patient
may
ear
symptom
although
bullou
myring
histor
link
mycoplasm
infect
appear
rare
find
fever
malais
coryza
headach
protract
nonproduct
cough
repres
major
clinic
find
pleurit
chest
pain
splint
older
adult
popul
occur
nurs
home
set
pneumonia
consid
predomin
caus
newer
studi
identifi
respiratori
virus
c
pneumonia
frequent
pathogen
well
aureu
gramneg
bacilli
sever
pneumonia
outbreak
pneumonia
occur
nurs
home
involv
legionella
chlamydia
influenza
parainfluenza
rsv
rhinoviru
sever
communityacquir
pneumonia
patient
cap
develop
sever
diseas
defin
admiss
icu
owe
presenc
shock
requir
vasopressor
respiratori
failur
requir
mechan
ventil
earli
identif
patient
higher
risk
develop
sever
pneumonia
import
patient
higher
mortal
rate
requir
support
care
furthermor
patient
sever
pneumonia
infect
differ
spectrum
etiolog
agent
would
therefor
benefit
differ
empir
antibiot
strategi
patient
less
sever
diseas
advanc
age
presenc
signific
comorbid
nurs
home
resid
immunosuppress
alter
mental
statu
believ
associ
develop
sever
cap
approxim
one
third
patient
sever
pneumonia
would
previous
healthi
pneumonia
organ
classic
associ
sever
pneumonia
howev
patient
requir
icu
admiss
increas
incid
aureu
l
pneumophila
gramneg
bacilli
especi
klebsiella
spp
h
influenza
addit
pneumocysti
increasingli
recogn
caus
sever
pneumonia
nonhivinfect
patient
impair
cellmedi
immun
due
organ
transplant
malign
sever
malnutrit
receipt
immunosuppress
therapi
includ
corticosteroid
antineoplast
chemotherapeut
agent
well
newer
agent
includ
inhibitor
rituximab
cap
gener
signific
geograph
differ
rel
incid
differ
pathogen
metaanalysi
studi
publish
indic
overal
mortal
rate
cap
patient
diseas
sever
enough
requir
icu
care
prognost
risk
factor
death
includ
male
sex
pleurit
chest
pain
hypothermia
systol
hypotens
tachypnea
diabet
mellitu
neoplast
diseas
neurolog
diseas
bacteremia
leukopenia
multilobar
radiograph
pulmonari
infiltr
although
shock
respiratori
failur
usual
evid
serv
major
criteria
defin
sever
pneumonia
patient
without
find
may
also
benefit
icu
care
past
decad
number
predict
rule
develop
assess
sever
prognosi
patient
pneumonia
includ
limit
pneumonia
sever
index
psi
confus
urea
respiratori
rate
low
blood
pressur
curb
score
curb
plu
age
older
score
without
urea
level
sever
communityacquir
pneumonia
scap
score
smartcop
score
risk
earli
admiss
intens
care
unit
reaicu
index
rule
vari
complex
well
sensit
specif
defin
need
icu
care
use
combin
factor
includ
age
gender
comorbid
condit
vital
sign
paramet
laboratori
radiograph
find
predict
either
need
icu
care
patient
prognosi
use
score
system
discuss
therapi
past
basic
distinct
epidemiolog
pneumonia
whether
infect
develop
commun
hospit
distinct
clinic
relev
import
variou
etiolog
agent
differ
antibiot
suscept
consequ
guidelin
empir
antibiot
therapi
differ
depend
infect
develop
increas
amount
health
care
deliveri
shift
outpati
set
even
complex
medic
condit
may
handl
without
hospit
subsequ
grow
number
patient
develop
pneumonia
extens
outpati
contact
variou
aspect
also
present
syndrom
acut
bacteri
cap
incid
pneumonia
vari
region
account
case
involv
hospit
legionella
spp
among
top
three
four
organ
caus
pneumonia
requir
care
icu
intern
studi
found
l
pneumophila
caus
case
legionella
pneumonia
approxim
case
caus
l
pneumophila
serogroup
inhal
aerosol
organ
exposur
environment
reservoir
fresh
water
moist
soil
usual
mean
acquir
organ
although
aspir
thought
altern
rout
infect
cigarett
smoke
chronic
lung
diseas
immunosuppress
consist
note
risk
factor
develop
diseas
although
earli
symptom
malais
muscl
ach
headach
nonproduct
cough
resembl
onset
viral
syndrom
rapid
progress
pulmonari
symptom
rel
high
fever
often
exceed
c
f
noteworthi
l
pneumophila
pneumonia
associ
varieti
extrapulmonari
find
laboratori
abnorm
includ
mental
statu
chang
abdomin
complaint
loos
stool
diarrhea
headach
bradycardia
elev
hepat
enzym
level
hypophosphatemia
hyponatremia
elev
serum
lactat
dehydrogenas
level
elev
serum
creatinin
level
find
mostli
reflect
sever
pneumonia
rather
specif
legionella
infect
extrapulmonari
infect
unusu
occur
usual
involv
heart
myocard
pericard
postcardiotomylik
syndrom
unfortun
none
find
distinguish
pneumonia
due
l
pneumophila
atyp
agent
typic
bacteri
pathogen
similarli
radiograph
manifest
distinguish
legionella
infect
caus
patchi
interstiti
infiltr
nodular
infiltr
may
progress
rapidli
even
adequ
therapi
characterist
pleural
effus
may
note
one
third
patient
clinic
set
aspir
occur
includ
diseas
state
conscious
alter
normal
gag
swallow
reflex
abnorm
ill
predispos
dysphagia
either
neurolog
diseas
upper
gastrointestin
tract
diseas
surgeri
condit
lead
mechan
disrupt
glottic
closur
tracheostomi
nasogastr
tube
recent
prospect
populationbas
studi
canadian
provinc
analyz
patient
hospit
pneumonia
identifi
aspir
caus
case
commun
case
continu
care
facil
commun
set
case
relat
impair
level
conscious
due
alcohol
drug
hepat
failur
case
due
dysphagia
continu
care
facil
predomin
risk
factor
dysphagia
neurolog
diseas
case
impair
level
conscious
major
risk
factor
addit
patient
pathogenesi
lung
injuri
due
acid
aspir
delin
presenc
acid
content
lung
induc
releas
proinflammatori
cytokin
includ
cytokin
recruit
neutrophil
lung
activ
neutrophil
appear
key
mediat
acut
lung
injuri
acid
aspir
although
role
complement
also
demonstr
although
aspir
may
wit
event
major
episod
silent
brought
medic
attent
sequela
three
major
syndrom
recogn
consequ
aspir
chemic
pneumon
bronchial
obstruct
secondari
aspir
particul
matter
bacteri
aspir
pneumonia
aspir
may
associ
acut
respiratori
distress
syndrom
atelectasi
bronchial
hyperreact
fibrosi
although
chemic
pneumon
mechan
obstruct
usual
caus
acut
symptom
aspir
pneumonia
insidi
symptom
usual
occur
gradual
sever
day
initi
episod
aspir
pneumon
necrot
pneumonia
abscess
empyema
common
symptom
often
includ
fever
weight
loss
product
cough
foulsmel
putrid
sputum
occur
commonli
anemia
elev
white
blood
cell
count
frequent
respiratori
distress
usual
seen
moist
crepit
rale
may
heard
sputum
product
variabl
sputum
purul
one
third
one
half
case
gram
stain
cultur
sputum
usual
reveal
mouth
microbiota
white
blood
cell
count
greater
uncommon
occur
approxim
patient
elev
sediment
rate
note
case
pulmonari
involv
seen
radiograph
commonli
extens
physic
examin
would
indic
unilater
bilater
patchi
infiltr
one
segment
usual
lower
lobe
note
bronchial
peribronchi
distribut
upper
lobe
involv
pleural
effus
less
common
may
seen
case
progress
radiograph
pictur
despit
stabl
clinic
pictur
may
seen
overal
clinic
cours
case
benign
disappear
constitut
symptom
usual
note
first
second
week
although
cough
radiograph
chang
may
persist
sever
week
occasion
pneumonia
infect
present
sever
cap
requir
intens
care
larg
number
extrapulmonari
manifest
may
occur
pneumonia
infect
includ
involv
skin
central
nervou
system
blood
kidney
see
chapter
c
pneumonia
emerg
import
caus
atyp
pneumonia
may
account
cap
case
often
seen
conjunct
pathogen
although
diseas
uncommon
younger
year
serolog
evid
infect
note
adult
recent
studi
suggest
import
role
chlamydia
cap
older
year
age
diseas
usual
occur
sporad
although
epidem
well
document
major
infect
either
asymptomat
produc
mild
symptom
mycoplasm
infect
sore
throat
hoars
herald
onset
pneumonia
although
progress
symptom
appear
slower
note
mycoplasm
viral
pneumonia
cough
may
begin
sever
day
week
suggest
biphas
ill
hoars
sinu
tender
appear
commonli
patient
infect
mycoplasma
virus
white
blood
cell
count
rare
elev
pneumonia
c
pneumonia
usual
mild
although
complet
recoveri
may
slow
cough
malais
may
persist
week
month
reinfect
occur
appear
milder
primari
infect
usual
associ
pneumonia
chronic
latent
infect
also
describ
infect
c
pneumonia
associ
exacerb
copd
asthma
gener
featur
distinguish
chlamydi
pneumonia
infect
caus
atyp
agent
bacteria
c
pneumonia
infect
associ
extrapulmonari
manifest
includ
otiti
sinus
pericard
myocard
endocard
also
associ
coronari
arteri
diseas
although
definit
relationship
remain
unclear
see
chapter
viral
agent
associ
atyp
pneumonia
adult
influenza
b
adenoviru
type
especi
militari
recruit
human
metapneumoviru
rsv
especi
older
adult
immunosuppress
patient
parainfluenza
viru
consid
common
advent
multiplex
realtim
pcr
assay
rapidli
expand
understand
role
viral
pathogen
acut
pneumonia
shown
rhinovirus
coronavirus
signific
pathogen
adult
human
bocaviru
human
metapneumoviru
caus
children
younger
year
age
moreov
presenc
two
viral
pathogen
uncommon
viral
agent
less
common
caus
pneumonia
includ
enterovirus
parechovirus
herpesvirus
hantavirus
mimivirus
measl
epidem
diseas
predominantli
link
influenza
sar
coronaviru
caus
worldwid
diseas
second
similar
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
pneumonia
identifi
see
chapter
elderli
patient
especi
comorbid
frequent
popul
greatest
risk
viral
pneumonia
legionella
recogn
import
caus
atyp
pneumonia
syndrom
although
patient
infect
legionella
may
scedosporium
apiospermum
cladosporium
herbarum
patient
churgstrauss
syndrom
frequent
eosinophilia
along
allerg
angiiti
granulomatosi
present
asthma
diffus
pulmonari
infiltr
multiorgan
involv
hypereosinophil
syndrom
eosinophil
granuloma
also
known
primari
pulmonari
langerhan
cell
histiocytosi
granulomatosi
bronchiol
obliteran
organ
pneumonia
syndrom
postirradi
pneumon
unusu
case
pulmonari
infiltr
eosinophilia
hap
second
common
caus
nosocomi
infect
associ
signific
morbid
mortal
lead
caus
infectionrel
death
hospit
patient
attribut
mortal
rate
report
higher
mortal
rate
observ
patient
bacterem
pneumonia
caus
p
aeruginosa
acinetobact
spp
morbid
associ
nosocomi
pneumonia
includ
longer
hospit
stay
averag
day
estim
attribut
cost
approxim
risk
factor
develop
nosocomi
pneumonia
categor
patient
relat
infect
control
relat
intervent
relat
patientrel
risk
factor
includ
age
older
year
sever
underli
diseas
malnutrit
coma
metabol
acidosi
presenc
number
comorbid
ill
eg
copd
alcohol
azotemia
central
nervou
system
dysfunct
infect
controlrel
risk
factor
includ
lack
hand
hygien
gloveus
practic
use
contamin
respiratori
equip
interventionrel
risk
factor
involv
procedur
therapi
undermin
normal
host
defens
allow
host
expos
larg
inocula
bacteria
sed
narcot
may
lead
aspir
corticosteroid
cytotox
agent
blunt
normal
host
respons
infect
prolong
use
antibiot
engend
resist
surgic
procedur
especi
involv
chest
abdomen
associ
chang
host
defens
predispos
pneumonia
use
ventil
support
perhap
greatest
risk
factor
develop
nosocomi
pneumonia
vap
occur
intub
patient
data
suggest
per
day
risk
develop
pneumonia
ventil
higher
risk
first
day
intub
use
antacid
blocker
rais
gastric
ph
shown
increas
stomach
colon
aerob
gramneg
rod
whether
lead
increas
nosocomi
pneumonia
remain
controversi
percentag
patient
vap
caus
organ
initi
found
stomach
rang
aerob
gramneg
bacilli
caus
case
nosocomi
pneumonia
member
enterobacteriacea
k
pneumonia
escherichia
coli
serratia
marcescen
acinetobact
spp
enterobact
spp
pseudomona
speci
account
major
increas
preval
highlevel
antibiot
resist
among
gramneg
bacilli
rel
incid
pneumonia
due
multidrugresist
bacteria
vari
institut
occasion
unit
within
institut
risk
factor
pathogen
includ
length
hospit
prior
antibiot
exposur
local
epidemiolog
factor
aureu
caus
nosocomi
pneumonia
mrsa
major
pathogen
set
contrast
promin
role
cap
pneumonia
h
influenza
togeth
caus
nosocomi
pneumonia
studi
predominantli
seen
infect
develop
earli
hospit
cours
limit
inform
compar
bacteriolog
vap
nonventilatorassoci
hap
avail
data
indic
gener
distribut
aerob
pathogen
rel
compar
although
increas
rel
preval
gramneg
pathogen
patient
vap
particularli
nonenter
gramneg
bacilli
although
use
sed
feed
tube
endotrach
tube
risk
factor
develop
aspir
pneumonia
lack
support
anaerob
microbiolog
test
led
pauciti
data
role
anaerob
bacteria
hap
one
studi
perform
earli
veteran
hospit
bacteriolog
analysi
research
laboratori
document
anaerob
associ
find
bacteriolog
find
aspir
pneumonia
reflect
microbiota
oropharynx
import
periodont
diseas
regard
note
studi
perform
patient
indol
diseas
use
techniqu
transtrach
aspir
analysi
anaerob
research
laboratori
document
anaerob
involv
major
case
either
alon
combin
oral
aerob
facult
anaerob
bacteroid
spp
porphyromona
spp
prevotella
melaninogenica
fusobacterium
spp
anaerob
gramposit
cocci
predomin
anaerob
isol
communityacquir
aspir
pneumonia
streptococcu
spp
h
influenza
common
aerob
isol
contrast
gramneg
bacilli
includ
p
aeruginosa
aureu
commonli
isol
aerob
nosocomi
aspir
pneumonia
includ
vap
well
pneumonia
occur
nurs
home
patient
eosinophil
pneumonia
pulmonari
infiltr
eosinophilia
pie
also
call
eosinophil
pneumonia
syndrom
associ
varieti
clinic
entiti
infecti
caus
pulmonari
eosinophilia
transient
peripher
pulmonari
infiltr
minim
symptom
syndrom
associ
ascari
strongyloid
hookworm
infect
ascari
probabl
lead
parasit
caus
syndrom
worldwid
prolong
pulmonari
eosinophilia
associ
weight
loss
fever
cough
dyspnea
may
due
tuberculosi
brucellosi
psittacosi
coccidioidomycosi
histoplasmosi
parasit
infect
includ
ascariasi
strongyloidiasi
paragonimiasi
echinococcosi
viscer
larval
migran
cutan
larva
migran
infect
schistosoma
dirofilaria
immiti
ancylostoma
speci
noninfecti
caus
includ
drug
allergi
sarcoidosi
eosinophil
leukemia
hodgkin
diseas
paraneoplast
syndrom
hypersensit
pneumon
eg
pigeon
breeder
diseas
pie
syndrom
associ
pneumocysti
pneumonia
acut
eosinophil
pneumonia
distinct
clinic
entiti
occur
younger
otherwis
healthi
individu
mark
acut
onset
dyspnea
nonproduct
cough
fever
sever
hypoxia
chest
pain
requir
icu
care
mechan
ventil
although
leukocytosi
common
peripher
eosinophilia
typic
minim
bilater
diffus
pulmonari
infiltr
common
radiograph
abnorm
usual
begin
interstiti
infiltr
progress
alveolar
infiltr
chest
ct
reveal
bilater
opac
bal
yield
mark
eosinophilia
diagnost
featur
diseas
although
patient
receiv
antibiot
rapid
stabil
occur
corticosteroid
use
suggest
chronic
eosinophil
pneumonia
may
repres
uniqu
clinic
entiti
may
continuum
asthma
churgstrauss
syndrom
subacut
onset
cough
dyspnea
fever
weight
loss
associ
peripher
eosinophilia
common
featur
unlik
situat
acut
eosinophil
pneumonia
respiratori
failur
rare
peripher
well
migratori
infiltr
commonli
seen
radiograph
interstiti
infiltr
alveolar
exud
predomin
eosinophil
characterist
patholog
featur
rapid
respons
corticosteroid
report
tropic
pulmonari
eosinophilia
consist
myalgia
fatigu
weight
loss
anorexia
associ
cough
frequent
nocturn
exacerb
wheez
dyspnea
mark
peripher
eosinophilia
patient
live
visit
tropic
case
believ
repres
immunolog
hyperrespons
microfilari
infect
wuchereria
bancrofti
brugia
malayi
radiograph
chang
distinct
includ
increas
interstiti
mark
nodul
throughout
lung
preferenti
involv
base
therapi
diethylcarbamazin
see
chapter
caus
pie
syndrom
includ
bronchopulmonari
mycosi
suspect
patient
pie
present
asthma
conjunct
bronchiectasi
recurr
expector
brown
mucu
plug
peripher
eosinophilia
although
predominantli
associ
chronic
bronchial
colon
aspergillu
speci
seen
conjunct
fungi
thorac
societi
bt
studi
use
four
clinic
paramet
includ
new
onset
confus
urea
level
greater
mmoll
respiratori
rate
greater
breathsmin
systol
blood
pressur
less
mm
hg
diastol
blood
pressur
less
mm
hg
presenc
two
criteria
suggest
increas
mortal
defin
sever
pneumonia
score
develop
later
ad
age
older
year
system
presenc
three
paramet
lead
predict
increas
mortal
modifi
index
elimin
inclus
blood
urea
determin
make
index
free
laboratori
test
allow
patient
assess
complet
bedsid
sever
compar
trial
variou
severityassess
indic
assess
util
indic
psi
tool
appear
rel
compar
predict
high
low
mortal
group
idsaat
bt
guidelin
support
use
three
sever
ill
score
assess
patient
cap
requir
laboratori
test
appear
optim
commun
primari
care
set
evid
use
sever
assess
indic
increas
percentag
patient
cap
receiv
outpati
treatment
howev
critic
recogn
sever
assess
index
serv
guidelin
absolut
clinic
judgment
regard
presenc
comorbid
condit
hypoxia
stabil
home
situat
abil
take
oral
medic
reliabl
take
medic
likelihood
return
followup
likelihood
call
help
need
play
role
decid
whether
patient
treat
home
hospit
addit
initi
valid
studi
psi
index
exclud
patient
hiv
infect
otherwis
immunocompromis
recent
hospit
recent
sever
studi
util
indic
patient
hcap
indic
use
patient
immunocompromis
data
still
limit
hcap
indic
applic
immunocompromis
patient
psi
indic
predict
risk
mortal
due
cap
appropri
level
inpati
care
requir
patient
note
previous
approxim
patient
cap
admit
icu
sever
addit
indic
recent
devis
defin
patient
could
benefit
level
care
includ
sever
communityacquir
pneumonia
scap
score
smartcop
score
risk
earli
admiss
intens
care
unit
reaicu
index
addit
idsaat
guidelin
recommend
major
minor
criteria
defin
patient
directli
admit
icu
independ
valid
major
criteria
either
septic
shock
requir
vasopressor
support
acut
respiratori
failur
requir
invas
mechan
ventil
presenc
three
follow
minor
criteria
also
indic
need
icu
care
increas
respiratori
rate
greater
equal
breathsmin
low
pao
fraction
inspir
oxygen
ratio
multilobar
infiltr
confusiondisorient
uremia
blood
urea
nitrogen
level
mgdl
leukopenia
white
blood
cell
count
cellsmm
thrombocytopenia
platelet
count
cellsmm
hypothermia
core
temperatur
c
f
hypotens
requir
aggress
fluid
resuscit
complex
addit
score
system
limit
present
util
advent
sophist
electron
medic
record
system
incorpor
diagnostictherapeut
algorithm
assist
use
remain
guidelin
applic
must
supplement
clinic
judgment
although
mild
case
selflimit
use
antimicrobi
agent
mainstay
treatment
pneumonia
reduc
microbi
burden
antimicrobi
therapi
reduc
durat
ill
risk
complic
mortal
rate
diagnost
studi
describ
previous
yield
like
caus
specif
narrowspectrum
therapi
initi
howev
patient
specif
case
nosocomi
pneumonia
second
recent
studi
identifi
anaerob
conjunct
aerob
microbiota
patient
vap
organ
consid
aspir
like
occur
pneumonia
caus
legionella
speci
may
occur
sporad
part
outbreak
respiratori
virus
influenza
parainfluenza
adenoviru
rsv
caus
sporad
nosocomi
pneumonia
well
occasion
institut
outbreak
recognit
herp
simplex
viru
cytomegaloviru
reactiv
identifi
patient
sever
vap
adult
respiratori
distress
syndrom
signific
reactiv
remain
uncertain
time
recent
consensu
guidelin
establish
concern
risk
etiolog
diagnost
workup
therapi
nosocomi
pneumonia
vap
indepth
review
present
chapter
pneumonia
immunocompromis
host
perhap
complex
pneumonia
syndrom
repres
interact
host
defens
defect
engend
underli
diseas
well
chemotherapi
diseas
exposur
potenti
pathogen
commun
within
hospit
set
reactiv
infecti
process
previous
dormant
cap
atyp
pneumonia
aspir
pneumonia
nosocomi
pneumonia
take
place
compromis
host
larg
number
bacteri
fungal
viral
noninfecti
caus
must
consid
see
discuss
chapter
first
decis
confront
clinician
whether
patient
present
respiratori
symptom
fact
pneumonia
difficulti
establish
diagnosi
clinic
ground
potenti
problem
overprescrib
empir
antibiot
patient
respiratori
find
review
chest
radiograph
usual
necessari
establish
definit
diagnosi
pneumonia
perform
patient
consid
ill
enough
consid
hospit
next
decis
whether
patient
hospit
whether
patient
need
admiss
icu
consequ
level
treatment
cost
care
associ
iatrogenesi
inpati
manag
increas
cost
care
cap
less
desir
patient
lowrisk
patient
associ
compar
clinic
outcom
numer
sever
assess
tool
develop
identifi
patient
sever
diseas
requir
hospit
icu
admiss
earlier
assess
tool
incorpor
combin
clinic
epidemiolog
laboratori
radiograph
paramet
assess
recent
develop
tool
focus
clinic
paramet
alon
evalu
bedsid
one
earliest
develop
wide
use
assess
tool
port
score
also
known
pneumonia
sever
index
psi
system
use
clinic
paramet
categori
age
presenc
comorbid
vital
sign
abnorm
laboratori
radiolog
find
base
point
system
five
prognost
group
v
defin
lowest
score
group
associ
low
mortal
highest
score
group
v
associ
highest
mortal
guidelin
hospit
patient
group
ii
usual
treat
outpati
patient
group
iii
borderlin
group
patient
group
iv
v
admit
either
routin
ward
icu
port
score
psi
valid
wide
endors
random
control
trial
confirm
patient
psi
group
ii
iii
respiratori
failur
complic
pleural
effus
unstabl
comorbid
condit
compar
clinic
outcom
whether
manag
inpati
outpati
limit
psi
system
rel
complex
sever
altern
score
system
develop
util
readili
obtain
paramet
includ
curb
score
curb
plu
age
greater
score
score
without
urea
level
curb
score
formul
british
diagnosi
establish
certainti
prior
onset
therapi
antibiot
regimen
must
select
empir
addit
target
like
expect
pathogen
primari
consider
select
specif
agent
treat
pneumonia
intrapulmonari
penetr
differ
agent
pharmacokinet
pharmacodynam
characterist
except
commerci
avail
antimicrobi
agent
achiev
adequ
intrapulmonari
concentr
use
treatment
pneumonia
although
signific
differ
tissu
penetr
one
agent
daptomycin
shown
bind
pulmonari
surfact
therebi
decreas
efficaci
treat
pneumonia
pharmacokinet
pharmacodynam
import
defin
appropri
antibiot
dose
compound
timedepend
killer
penicillin
cephalosporin
carbapenem
use
activ
drug
level
need
minim
inhibitori
concentr
mic
organ
treat
dose
interv
optim
outcom
parenter
administr
aminoglycosid
lead
low
concentr
bronchial
fluid
given
use
tradit
dose
serum
peak
level
least
gentamicin
tobramycin
amikacin
need
success
outcom
treat
gramneg
pneumonia
howev
aminoglycosid
show
concentrationdepend
kill
signific
postantibiot
effect
improv
clinic
outcom
achiev
use
pharmacodynam
model
optim
dose
retrospect
pharmacodynam
pharmacokinet
analysi
efficaci
vancomycin
treatment
aureu
pneumonia
indic
clinic
cure
correl
area
curv
auc
mic
ratio
greater
equal
indic
optim
dose
target
vancomycin
trough
level
unfortun
even
highlevel
vancomycin
therapi
may
effect
treat
strain
aureu
mic
greater
equal
empir
antimicrobi
regimen
select
treat
acut
pneumonia
depend
clinic
situat
sever
profession
societi
includ
idsa
at
bt
pediatr
infecti
diseas
societi
develop
guidelin
manag
cap
idsa
at
publish
joint
guidelin
manag
hap
vap
hcap
adult
adult
cap
idsaat
guidelin
bt
recommend
stratifi
patient
outpati
versu
inpati
treatment
base
psi
score
system
although
bt
recommend
use
score
patient
seen
commun
primari
care
set
guidelin
recognit
like
etiolog
agent
given
clinic
situat
recognit
organ
like
caus
morbid
mortal
emphas
final
preval
common
antibiot
resist
pattern
risk
acquisit
recogn
empir
antibiot
therapi
cap
children
adult
well
hcap
review
tabl
reader
refer
chapter
recommend
empir
manag
hap
patient
requir
hospit
clear
distinct
typic
eg
pneumococc
atyp
mycoplasm
chlamydi
pneumonia
made
type
organ
cover
risk
presenc
drugresist
pneumonia
assess
use
previou
antibiot
especi
macrolid
fluoroquinolon
prior
month
well
resid
longterm
care
facil
predict
presenc
resist
macrolid
fluoroquinolon
risk
drugresist
pneumonia
infect
low
oral
agent
highdos
amoxicillin
amoxicillinclavulan
cefuroxim
axetil
azalidesmacrolid
azithromycin
clarithromycin
erythromycin
respiratori
tract
quinolon
levofloxacin
gemifloxacin
moxifloxacin
adequ
choic
doxycyclin
trimethoprimsulfamethoxazol
may
use
concern
increas
incid
resist
agent
strain
pneumococci
increas
resist
azalidemacrolid
agent
due
blockag
ribosom
bind
area
encod
ermb
gene
also
becom
problem
pneumonia
therapeut
failur
note
although
suggest
agent
may
use
long
resist
rate
less
recent
analysi
suggest
resist
level
high
associ
increas
morbid
mortal
patient
increas
risk
poor
outcom
age
underli
diseas
risk
infect
resist
pneumococci
exist
owe
prior
antibiot
use
respiratori
tract
quinolon
agent
like
effect
current
activ
strain
pneumonia
includ
penicillinresist
strain
ad
benefit
activ
atyp
agent
although
increas
resist
potenti
problem
increas
use
quinolon
yet
emerg
signific
problem
plu
macrolid
compar
regimen
regardless
initi
choic
antibiot
organ
isol
coverag
narrow
possibl
basi
suscept
test
result
patient
ill
enough
requir
hospit
treat
parenter
agent
cover
like
pathogen
whether
benefit
antibiot
combin
set
remain
ongo
question
combin
therapi
antibiot
macrolid
especi
azithromycin
associ
studi
decreas
mortal
decreas
length
hospit
stay
howev
benefit
decreas
appar
random
control
trial
studi
address
guidelineconcord
therapi
addit
potenti
slight
benefit
combin
therapi
azithromycin
counterbalanc
small
increas
risk
sudden
death
due
cardiovascular
event
individu
preexist
cardiovascular
risk
factor
choic
individu
would
ceftriaxon
cefotaxim
plu
azithromycin
except
patient
high
risk
cardiovascular
diseas
respiratori
fluoroquinolon
seem
prefer
factor
suggest
specif
etiolog
gram
stain
reveal
specif
antibiot
coverag
use
although
regimen
repres
basic
cours
therapi
specif
clinic
circumst
may
warrant
variat
exampl
aureu
pneumonia
includ
communityassoci
mrsa
consid
influenza
outbreak
even
though
pneumonia
still
major
etiolog
agent
agent
activ
mrsa
util
reason
suspect
presenc
caus
pneumonia
linezolid
vancomycin
beststudi
agent
treatment
mrsa
pneumonia
clindamycin
also
appear
effect
children
prospect
control
trial
compar
linezolid
vancomycin
hap
hcap
due
mrsa
found
better
initi
clinic
outcom
patient
treat
linezolid
differ
mortal
day
new
cephalosporin
ceftarolin
good
vitro
activ
mrsa
isol
may
prove
anoth
altern
treatment
mrsa
pneumonia
although
clinic
trial
use
set
current
avail
patient
found
methicillinsuscept
aureu
pneumonia
treatment
nafcillin
oxacillin
prefer
current
clinic
efficaci
data
use
trimethoprimsulfamethoxazol
fluoroquinolon
doxycyclin
tigecyclin
treatment
staphylococc
pneumonia
avail
anaerob
aspir
pneumonia
possibl
patient
develop
pneumonia
loss
conscious
due
drug
alcohol
neurolog
diseas
agent
activ
oral
anaerob
need
includ
ampicillinsulbactam
clindamycin
otherwis
clinic
trial
suggest
target
anaerob
coverag
requir
major
case
cap
aerob
gramneg
bacilli
includ
p
aeruginosa
caus
cap
case
risk
factor
previous
note
gramneg
pneumonia
therefor
sought
gramneg
bacilli
suspect
infect
p
aeruginosa
concern
therapi
antipseudomon
compound
eg
cefepim
ceftazidim
piperacillintazobactam
imipenem
meropenem
reason
choic
pseudomona
involv
exclud
agent
cefotaxim
ceftriaxon
ertapenem
could
consid
debat
exist
whether
combin
therapi
agent
either
aminoglycosid
quinolon
improv
outcom
gramneg
pneumonia
data
exist
support
side
controversi
although
increas
evid
initi
combin
therapi
decreas
risk
initi
recent
antibiot
therapi
respiratori
fluoroquinolon
alon
advanc
macrolid
plu
intraven
g
recent
antibiot
therapi
advanc
macrolid
plu
intraven
respiratori
fluoroquinolon
alon
regimen
select
depend
natur
recent
antibiot
therapi
pseudomona
infect
concern
g
plu
either
advanc
macrolid
respiratori
fluoroquinolon
pseudomona
infect
concern
patient
allergi
respiratori
fluoroquinolon
without
clindamycin
pseudomona
infect
concern
h
cystic
fibrosi
impair
host
defens
either
antipseudomon
plu
ciprofloxacin
mg
iv
mg
po
antipseudomon
agent
plu
aminoglycosid
j
plu
respiratori
fluoroquinolon
macrolid
pseudomona
infect
concern
patient
allergi
aztreonam
g
iv
plu
aminoglycosid
plu
respiratori
fluoroquinolon
health
careassoci
pneumonia
k
either
antipseudomon
plu
ciprofloxacin
levofloxacin
antipseudomon
agent
plu
aminoglycosid
plu
respiratori
fluoroquinolon
macrolid
plu
vancomycin
linezolid
mrsa
coverag
azithromycin
clarithromycin
erythromycin
b
patient
given
cours
antibiot
treatment
infect
within
past
month
exclud
current
episod
infect
treatment
risk
factor
drugresist
streptococcu
pneumonia
possibl
infect
gramneg
bacilli
depend
class
antibiot
recent
given
one
anoth
suggest
option
may
select
recent
use
fluoroquinolon
dictat
select
nonfluoroquinolon
regimen
vice
versa
c
moxifloxacin
mg
daili
gemifloxacin
mg
daili
levofloxacin
mg
daili
azithromycin
mg
daili
clarithromycin
mg
twice
daili
erythromycin
mg
four
time
day
e
highdos
amoxicillin
g
three
time
day
highdos
amoxicillinclavulan
g
twice
daili
cefpodoxim
mg
twice
daili
cefuroxim
mg
twice
daili
f
vancomycin
dose
target
vancomycin
trough
level
linezolid
mg
twice
daili
g
cefotaxim
g
iv
ceftriaxon
g
iv
daili
ampicillin
g
iv
ampicillinsulbactam
g
iv
ertapenem
g
iv
daili
h
risk
factor
pseudomona
infect
includ
sever
structur
lung
diseas
eg
bronchiectasi
recent
antibiot
therapi
health
careassoci
exposur
stay
hospit
especi
icu
patient
communityacquir
pneumonia
icu
coverag
pneumonia
legionella
speci
must
alway
consid
piperacillin
g
iv
piperacillintazobactam
g
iv
imipenem
mg
iv
meropenem
g
iv
ceftazidim
g
iv
cefepim
g
iv
excel
adequ
pneumonia
h
influenza
infect
may
prefer
concern
rel
unusu
pathogen
communityacquir
pneumonia
p
aeruginosa
klebsiella
speci
gramneg
bacteria
j
data
suggest
older
adult
receiv
aminoglycosid
wors
outcom
tradit
dose
aminoglycosid
achiev
peak
level
least
gentamicin
tobramycin
amikacin
trough
less
gentamicin
tobramycin
less
amikacin
oncedaili
dose
gentamicin
tobramycin
mgkg
iv
trough
target
mgkg
iv
amikacin
trough
target
presum
bacteri
oral
amoxicillin
mgkgday
dose
maximum
gday
oral
amoxicillinclavulan
amoxicillin
compon
mgkgday
dose
maximum
dose
mgday
add
macrolid
distinguish
bacteri
atyp
presum
atyp
oral
azithromycin
mgkg
day
follow
mgkgday
daili
day
maximum
mg
day
follow
mg
day
oral
clarithromycin
mgkgday
dose
maximum
gday
erythromycin
doxycyclin
children
yr
old
continu
classic
durat
care
unsupport
evid
recent
data
indic
clinic
stabil
defin
normal
previous
abnorm
physiolog
paramet
includ
heart
rate
respiratori
rate
oxygen
blood
pressur
mental
state
abil
care
oneself
occur
rel
quickli
patient
hospit
cap
see
tabl
physiolog
abnorm
correct
day
normal
physiolog
abnorm
gener
occur
day
patient
sever
ill
gener
take
longer
stabil
addit
monitor
least
reduct
creactiv
protein
suggest
addit
measur
defin
clinic
stabil
appear
benefici
patient
sever
diseas
costeffect
approach
assess
overal
stabil
achiev
clinic
relaps
seriou
enough
requir
icu
care
occur
less
time
oral
antibiot
therapi
safe
clinic
stabil
reach
even
patient
sever
cap
clear
use
observ
patient
within
hospit
switch
oral
therapi
howev
import
recogn
discharg
patient
stabil
reach
may
lead
increas
rehospit
death
use
definit
clinic
stabil
shown
greater
number
factor
remain
abnorm
discharg
greater
chanc
readmiss
death
studi
durat
therapi
pneumonia
prospect
wellcontrol
use
antibiot
dose
schedul
vari
durat
therapi
howev
studi
found
period
less
day
short
day
azithromycin
effect
longer
durat
therapi
mild
moder
cap
age
presenc
underli
comorbid
includ
immun
compromis
virul
pathogen
clinic
stabil
may
delay
therefor
durat
antibiot
therapi
may
lengthen
current
adult
patient
inappropri
therapi
favor
initi
combin
therapi
patient
sever
ill
least
cultur
result
sputum
blood
avail
confirm
agent
given
vitro
activ
presum
organ
patient
allerg
penicillin
aztreonam
respiratori
tract
fluoroquinolon
without
aminoglycosid
could
use
patient
admit
icu
therapi
direct
pneumonia
penicillinresist
strain
legionella
spp
gramneg
rod
pneumonia
infect
p
aeruginosa
unlik
recent
hospit
recent
antibiot
use
pulmonari
comorbid
gramneg
rod
gram
stain
plu
either
azalidemacrolid
respiratori
tract
fluoroquinolon
would
therapi
first
choic
ceftriaxon
cefotaxim
would
reason
choic
pseudomona
infect
exclud
antipseudomon
cefepim
imipenem
meropenem
doripenem
piperacillintazobactam
plu
respiratori
tract
fluoroquinolon
azalidemacrolid
could
use
favor
cefepim
piperacillintazobactam
plu
respiratori
tract
fluoroquinolon
aminoglycosid
could
ad
third
agent
synergi
pseudomona
evid
literatur
favor
one
regimen
lack
retrospect
review
medicar
patient
hospit
suggest
antibiot
therapi
given
within
hour
present
associ
decreas
mortal
second
retrospect
studi
similar
design
show
antibiot
given
within
hour
present
would
result
lower
mortal
neither
studi
correct
caus
pneumonia
antibiot
use
despit
lack
prospect
random
studi
advis
regulatori
agenc
includ
joint
commiss
center
medicar
medicaid
servic
began
use
rule
core
qualiti
measur
subsequ
studi
found
attempt
meet
perform
standard
led
increas
misdiagnos
potenti
inappropri
antibiot
prescrib
emerg
depart
patient
failur
hospit
meet
standard
associ
increas
inpati
mortal
patient
admit
cap
hospit
perform
standard
subsequ
elimin
still
strong
evid
delay
antibiot
therapi
impact
outcom
patient
sepsi
idsaat
guidelin
current
recommend
antibiot
therapi
pneumonia
start
soon
diagnosi
consid
like
recent
durat
antibiot
therapi
pneumonia
base
anecdot
pattern
behavior
studi
address
appropri
durat
treatment
recent
studi
control
factor
found
impact
recent
statin
use
incid
sever
sepsi
mortal
cap
although
adjunct
therapi
describ
includ
use
activ
protein
c
noninvas
mechan
ventil
anticoagul
immunoglobulin
granulocyt
colonystimul
factor
probiot
chest
physiotherapi
antiplatelet
drug
overthecount
cough
medic
agonist
inhal
nitric
oxid
angiotensinconvert
enzym
inhibitor
clinic
trial
none
approach
shown
signific
role
therapi
vaccin
influenza
pneumonia
import
intervent
prevent
pneumonia
older
adult
influenza
vaccin
decreas
incid
hospit
pneumonia
mortal
efficaci
demonstr
consecut
influenza
season
influenza
vaccin
suggest
person
month
age
older
age
underli
diseas
risk
influenzarel
complic
includ
person
older
year
nurs
home
resid
peopl
chronic
pulmonari
cardiac
diseas
chronic
diseas
diabet
renal
failur
hematolog
disord
patient
immunosuppress
take
chronic
salicyl
therapi
women
second
third
trimest
pregnanc
health
care
worker
worker
nurs
home
provid
care
older
adult
debilit
person
also
target
influenza
vaccin
pneumococc
polysaccharid
vaccin
pneumococc
conjug
vaccin
licens
unit
state
although
good
clinic
data
show
vaccin
provid
protect
bacteremia
invas
pneumococc
diseas
yet
data
show
efficaci
vaccin
prevent
pneumonia
pneumococc
polysaccharid
pneumococc
conjug
vaccin
approv
use
adult
older
year
age
pneumococc
vaccin
recommend
patient
older
recov
cap
discuss
efficaci
vaccin
provid
chapter
activ
smoke
clear
risk
factor
bacteri
pneumonia
promot
smoke
cessat
compon
pneumonia
prevent
cap
idsaat
guidelin
recommend
minimum
least
day
antibiot
therapi
patient
afebril
hour
lack
one
sign
clinic
stabil
similarli
bt
guidelin
recommend
day
appropri
antibiot
therapi
patient
lowor
moderatesever
cap
treat
either
outpati
inpati
longer
therapi
consid
patient
highsever
diseas
bacterem
aureu
pneumonia
cavitari
diseas
pediatr
infecti
diseas
societyidsa
guidelin
cap
children
note
day
treatment
best
studi
children
although
shorter
cours
treatment
like
effect
although
earli
studi
found
limit
benefit
concord
process
care
measur
clinic
outcom
pneumonia
recent
evid
indic
complianc
clinic
practic
guidelin
cap
hcap
associ
decreas
inpati
mortal
inpati
length
stay
use
inpati
critic
pathway
base
clinic
practic
guidelin
reduc
inpati
length
stay
without
increas
advers
effect
discharg
outpati
followup
coordin
patient
cap
relat
residu
symptom
includ
fever
cough
short
breath
chest
pain
sputum
product
fatigu
gastrointestin
symptom
comorbid
particularli
cardiopulmonari
neurolog
diseas
frequent
reason
subsequ
earli
readmiss
among
patient
achiev
clinic
stabil
adjunct
therapi
robust
inflammatori
respons
invad
pathogen
lead
potenti
wors
outcom
pneumonia
use
antiinflammatori
agent
could
potenti
benefit
demonstr
improv
outcom
addit
corticosteroid
therapi
pneumocysti
pneumonia
macrolid
famili
shown
vitro
immunomodulatori
activ
may
contribut
efficaci
cap
number
random
control
trial
investig
efficaci
corticosteroid
therapi
cap
use
differ
dosag
agent
date
evid
impact
overal
mortal
although
corticosteroid
may
shorten
overal
inpati
length
stay
day
statin
also
possess
antiinflammatori
properti
impact
cap
assess
observ
studi
although
initi
suggest
evid
benefit
studi
random
control
